Drug delivery carrier and drug preparation for co-delivering multiple therapeutic agents using the same
By using cationic liposomes and cationic materials modified by membrane-penetrating peptides in drug delivery vehicles, the problems of drug penetration ability and coordinated delivery of multiple therapeutic agents in the prior art are solved, and more efficient therapeutic effects are achieved.
Patent Information
- Application Number
- CN202011214492.6
- Authority / Receiving Office
- CN · China
- Patent Type
- Patents(China)
- Current Assignee / Owner
- Filing Date
- 2020-11-04
- Publication Date
- 2024-12-03
- Estimated Expiration
- 2040-11-04
AI Technical Summary
Existing drug delivery vehicles are inefficient in penetrating biofilm barriers and are difficult to deliver multiple therapeutic agents to the same lesion site at the same time, resulting in unsatisfactory treatment results.
A drug delivery vehicle containing cationic liposomes and cationic materials modified by membrane-penetrating peptides was developed, using membrane-penetrating peptides to covalently bond with polyethylene glycol phospholipids to bind cationic materials such as polyamino acids, PEI, penetratin or PAMAM. , form a drug delivery system with improved penetration ability.
The synergistic effect of multiple therapeutic agents is achieved, which significantly improves the therapeutic effect. By adjusting the particle size and charge ratio, the stability of the drug and deep tissue delivery are ensured.
Smart Images

Figure BDA0002759901930000091 
Figure BDA0002759901930000101 
Figure BDA0002759901930000181
Abstract
Description
Technical Field
[0001] The present invention relates to a drug delivery carrier, a method for preparing a pharmaceutical preparation using the drug delivery carrier, and a pharmaceutical preparation prepared thereby. Specifically, the drug delivery carrier of the present invention comprises a cationic liposome modified with a cell-penetrating peptide and a cationic material, wherein the cationic liposome modified with a cell-penetrating peptide comprises a cell-penetrating peptide covalently bonded to a polyethylene glycol phospholipid. The drug delivery carrier of the present invention can be used to prepare a pharmaceutical preparation for co-delivering multiple therapeutic agents, the particle size of the pharmaceutical preparation being between 50nm and 300nm, having good stability, being able to simultaneously deliver multiple therapeutic agents to the same lesion site, allowing multiple therapeutic agents to exert a synergistic therapeutic effect, and significantly improving the therapeutic effect. Background Art
[0002] Cell-penetrating peptide (CPP) is a short peptide with positive charge under physiological conditions, which can covalently or non-covalently connect to drug molecules such as genes, peptides and proteins, and deliver drug molecules into cells or carry drug molecules to penetrate biological membrane barriers. However, the ability of a single cell-penetrating peptide to carry drug molecules is very limited, which leads to a large particle size and poor stability of the complex formed by the cell-penetrating peptide and drug molecules.
[0003] In addition, the carriers for delivering drug molecules (such as genes, peptides and proteins) in the prior art, such as liposomes, have problems such as difficulty in penetrating the biomembrane barrier, low delivery efficiency and unsatisfactory efficacy. In the field of liposome research, how to improve the ability of liposomes to penetrate the biomembrane barrier, and use liposomes to simultaneously encapsulate a variety of different therapeutic drugs, more efficiently deliver a variety of drug molecules to the same lesion site, exert the synergistic effect of multiple drugs, and improve the therapeutic effect of the disease is still a huge challenge.
[0004] Therefore, there is still a need in the art for new drug delivery vectors using cell-penetrating peptides for co-delivering multiple therapeutic agents, and after the multiple therapeutic agents are simultaneously delivered to the same lesion site, the therapeutic agents exert synergistic effects to improve the therapeutic effect. SUMMARY OF THE INVENTION
[0005] The present inventors have developed a novel drug delivery carrier utilizing a cell-penetrating peptide through intensive research, which comprises a cationic liposome modified with a cell-penetrating peptide and a cationic material, wherein the cationic liposome modified with a cell-penetrating peptide comprises a cell-penetrating peptide covalently bonded to a polyethylene glycol phospholipid, and the cationic material is selected from a positively charged polyamino acid, polyethyleneimine (PEI), penetratin or a derivative of penetratin, and polyamidoamine (PAMAM).
[0006] In one embodiment, the cell-penetrating peptide in the drug delivery vector of the present invention is penetratin or a lipophilic derivative of penetratin having the following amino acid sequence:
[0007] R X1 IKIWF X2X3 RRMKWKK (SEQ ID NO: 1)
[0008] Wherein, X1, X2 and X3 are independently selected from the amino acids glutamine (glutamine, Q), asparagine (asparagine, N), alanine (alanine, A), valine (valine, V), leucine (leucine, L), isoleucine (isoleucine, I), proline (proline, P), phenylalanine (phenylalanine, F), tryptophan (tryptophan, W), methionine (methionine, M) and amino acids α-aminobutyric acid (α-aminobutyric acid), α-aminopentanoic acid (α-aminopentanoic acid), α-aminohexanoic acid (α-aminohexanoic acid), α-aminoheptanoic acid (α-aminoheptanoic acid) of natural origin. For example, some of the transmembrane peptides in the drug delivery carrier of the present invention are Penetratin derivatives in which the 2nd glutamine (Q) and / or the 8th glutamine (Q) and / or the 9th asparagine (N) of Penetratin are mutated to hydrophobic amino acids.
[0009] In one embodiment, the membrane-penetrating peptide-modified cationic liposome in the drug delivery carrier of the present invention comprises the following membrane materials:
[0010] (i) Cationic lipids, including but not limited to: 1,2-di-O-octadecenyl-3-trimethylammonium propane (DOTMA); dimethyldioctadecyl ammonium (DDAB); 1,2-dioleoyl-3-trimethylammonium-propane (DOTAP); 1,2-dioleoyl-3-dimethylammonium-propane (DODAP); 1,2-diacyloxy-3-dimethylammonium propane; 1,2-dialkoxy-3-dimethylammonium propane; dioctadecyl dimethyl ammonium chloride (DODAC), 1,2-dimyristoyloxypropyl-1,3-dimethylhydroxyethylammonium (DMRIE) and 2,3-dioleoyloxy-N-[2(sperminecarboxamide)ethyl]-N,N-dimethyl-1-propane trifluoroacetate ammonium (DOSPA) and combinations thereof. Preferably, DOTMA, DOTAP, DODAC and DOSPA are used. Most preferably, DOTAP is used;
[0011] (ii) non-cationic lipids, including but not limited to: 1,2-di-(9Z-octadecanoyl)-sn-glycero-3-phosphoethanolamine (DOPE), 1,2-dioleoyl-sn-glycero-3-phosphocholine (DOPC), 1,2-distearoyl-sn-glycero-3-phosphocholine (DSPC), 1,2-dipalmitoyl-sn-glycero-3-phosphocholine (DPPC), 1,2-dipalmitoyl-sn-glycero-3-phosphoethanolamine (DPPE), 1,2-dimyristoyl-sn-glycero-3-phosphoethanolamine (DMPE), 2-dioleoyl-sn-glycero-3-phospho-(1'-rac-glycerol) (DOPG) and combinations thereof. Preferably, it is DOPE and / or DOPC. Most preferably, it is DOPE;
[0012] (iii) cholesterol; and
[0013] (iv) PEGylated phospholipids and PEGylated phospholipids conjugated to CPP, such as phosphatidylcholine, phosphatidylethanolamine, phosphatidylinositol and sphingomyelin. Preferably, the PEGylated phospholipids are such as polyethylene glycol-distearoylphosphatidylethanolamine (PEG-DSPE) and its derivative methoxy-polyethylene glycol-distearoylphosphatidylethanolamine (mPEG-DSPE), and the PEGylated phospholipids conjugated to CPP are such as penetratin / penetratin derivative-PEG-DSPE.
[0014] In the present invention, cationic liposomes not modified with a cell-penetrating peptide are sometimes referred to as cationic liposomes (abbreviated as CLS), which comprise the above-mentioned membrane materials (i), (ii) and (iii).
[0015] In some embodiments, the molar ratio of membrane material (i): (ii): (iii): (iv) is about 20-40: 20-40: 20-40: 1-20, and the polyethylene glycol phospholipid conjugated with CPP accounts for about 20%-80% of the molar ratio in membrane material (iv). In some specific embodiments, the molar ratio of membrane material (i): (ii): (iii): (iv) is about 27.0-31.6: 27.0-31.6: 31.6-39.6: 1-10, and the polyethylene glycol phospholipid conjugated with CPP accounts for about 20%-80% of the molar ratio in membrane material (iv).
[0016] In some specific embodiments, the membrane-penetrating peptide-modified cationic liposomes in the drug delivery carrier of the present invention comprise the following membrane materials: (i) DOTAP; (ii) DOPE; (iii) cholesterol; (iv) mPEG 2000 -DSPE and 89W Penetratin-PEG3400 -DSPE, and the molar ratio of membrane materials (i):(ii):(iii):(iv) is about 20-40:20-40:20-40:1-20, and 89W Penetratin-PEG 3400 -DSPE accounts for about 20% to 80% by mole in the membrane material (iv). In some embodiments, the mole ratio of membrane material (i): (ii): (iii): (iv) is about 27.0-31.6: 27.0-31.6: 31.6-39.6: 1-10, and 89W Penetratin-PEG 3400 -DSPE accounts for about 20% to 80% molar ratio in the membrane material (iv). In some embodiments, the cationic liposomes in the drug delivery carrier of the present invention are composed of the following membrane materials: (i) DOTAP; (ii) DOPE; (iii) cholesterol; (iv) mPEG 2000 -DSPE and 89W Penetratin-PEG 3400 -DSPE, and the molar ratio of membrane materials (i):(ii):(iii):(iv) is about 28.5:28.5:38:5, 89W Penetratin-PEG 3400 - DSPE accounts for about 20%, 25%, 30%, 35%, 40%, 45%, 50%, 55%, 60%, 65%, 70%, 75%, 80% by mole in the membrane material (iv).
[0017] In another aspect, the present invention provides a pharmaceutical formulation for co-delivery of multiple therapeutic agents, the multiple therapeutic agents comprising at least one non-nucleic acid therapeutic agent and at least one nucleic acid therapeutic agent, which is prepared using the drug delivery vector of the present invention.
[0018] In one embodiment, a physical complex of a cationic material-at least one nucleic acid therapeutic agent is formed by mixing a cationic material and at least one nucleic acid therapeutic agent contained in a drug delivery vehicle;
[0019] The liposomes encapsulating at least one non-nucleic acid therapeutic agent are prepared by combining a membrane material of a cationic liposome and at least one non-nucleic acid therapeutic agent;
[0020] preparing a lipoplex by mixing the physical complex of the cationic material-at least one nucleic acid therapeutic agent with the liposome encapsulating at least one non-nucleic acid therapeutic agent;
[0021] The lipoplex is modified with a cell-penetrating peptide to prepare the pharmaceutical preparation, for example, the lipoplex is mixed with a polyethylene glycol (PEGylated) phospholipid and a polyethylene glycol phospholipid conjugated with a cell-penetrating peptide to perform cell-penetrating peptide modification to prepare the pharmaceutical preparation.
[0022] In one embodiment, a physical complex of a cationic material-at least one nucleic acid therapeutic agent is formed by mixing a cationic material and at least one nucleic acid therapeutic agent contained in a drug delivery vehicle;
[0023] The liposomes encapsulating at least one non-nucleic acid therapeutic agent are prepared by mixing all membrane materials of the cationic liposome modified with a membrane-penetrating peptide and at least one non-nucleic acid therapeutic agent;
[0024] The pharmaceutical preparation is prepared by mixing the physical complex of the cationic material-at least one nucleic acid therapeutic agent with the liposomes encapsulating at least one non-nucleic acid therapeutic agent.
[0025] There is no particular limitation on the at least one non-nucleic acid therapeutic agent to be delivered, including but not limited to chemotherapeutic agents, such as platinum drugs (e.g., cisplatin, carboplatin, oxaliplatin), taxane drugs (e.g., paclitaxel, docetaxel (DTX)), etoposide, irinotecan, pemetrexed, gemcitabine, melphalan, carmustine (BCNU), doxorubicin (DOX), bortezomib, methotrexate, imatinib, bleomycin, vinca alkaloids (e.g., vinblastine).
[0026] There is no particular limitation on the at least one nucleic acid therapeutic agent to be delivered, including but not limited to plasmid DNA, RNA such as small interfering RNA (siRNA), miRNA, sense RNA, antisense oligonucleotides (ASO), aptamers, ribozymes and the like. For example, the nucleic acid therapeutic agent is an RNA targeting brain diseases such as brain tumors (e.g., gliomas), such as siRNA targeting c-myc.
[0027] In one embodiment, the molar ratio of the non-nucleic acid therapeutic agent (e.g., chemotherapeutic drug) in the pharmaceutical formulation to the cationic lipid (e.g., DOTAP) in the cationic liposome is about 1:1500 to 2000:1, for example, about 1:1200, 1:1000, 1:500, 1:200, 1:100, 1:5, 5:1, 100:1, 200:1, 500:1, 1000:1, 1200:1, 1400:1, 1600:1, 1800:1; preferably about 1:1000 to 2000:1, further preferably about 1:500 to 500:1.
[0028] In one embodiment, the charge ratio of the cationic material (e.g., oligoarginine, PEI, penetratin or a derivative of penetratin, PAMAM) and the nucleic acid therapeutic agent in the pharmaceutical formulation is between 1:1 and 30:1, e.g., 1:1, 5:1, 10:1, 15:1, 20:1, 25:1, 30:1.
[0029] In one embodiment, the charge ratio of the cationic liposomes to the nucleic acid therapeutic agent in the pharmaceutical formulation is between 1:1 and 30:1, e.g., 2:1, 3:1, 4:1, 5:1, 6:1, 8:1, 10:1, 12:1.
[0030] In one embodiment, the drug loading of the pharmaceutical preparation for non-nucleic acid therapeutic agents (e.g., chemotherapeutic agents) is: the non-nucleic acid therapeutic agent (e.g., chemotherapeutic agent) accounts for about 0.01%-40% (w / w) of the pharmaceutical preparation, preferably about 0.02%-25% (w / w). In a specific embodiment, the drug loading of the pharmaceutical preparation for docetaxel (DTX) is 0.04% w / w.
[0031] In one embodiment, the charge ratio of the cationic material (e.g., oligoarginine, PEI, penetratin or a derivative of penetratin, PAMAM) and the nucleic acid therapeutic agent to be delivered in the pharmaceutical formulation is between 1:1 and 30:1, preferably 5:1; and the charge ratio of the cationic liposome to the nucleic acid therapeutic agent is between 1:1 and 30:1, preferably 4:1.
[0032] In one embodiment, the pharmaceutical preparation of the present invention has a particle size between 50 nm and 300 nm, preferably between 80 nm and 150 nm, and has good stability, can provide better protection for the various therapeutic agents contained therein, and is more conducive to delivering siRNA and drugs to deep tissues of the lesion site.
[0033] In another aspect, a method for preparing the pharmaceutical preparation of the present invention is provided, comprising:
[0034] (a) mixing the cationic material and at least one nucleic acid therapeutic agent contained in the drug delivery carrier of the present invention to form a physical complex of the cationic material and at least one nucleic acid therapeutic agent;
[0035] (b) preparing liposomes encapsulating at least one non-nucleic acid therapeutic agent using a membrane material of a cationic liposome and at least one non-nucleic acid therapeutic agent;
[0036] (c) preparing a liposome by mixing the physical complex of the cationic material-at least one nucleic acid therapeutic agent with the liposome encapsulating at least one non-nucleic acid therapeutic agent; and
[0037] (d) The lipoplex is modified with polyethylene glycolated (PEGylated) phospholipids and PEGylated phospholipids conjugated with a cell-penetrating peptide.
[0038] Alternatively, a method for preparing the pharmaceutical preparation of the present invention is provided, comprising
[0039] (a) mixing the cationic material and at least one nucleic acid therapeutic agent contained in the drug delivery carrier of the present invention to form a physical complex of the cationic material and at least one nucleic acid therapeutic agent;
[0040] (b) using all membrane materials of the cationic liposome modified with a membrane-penetrating peptide and at least one non-nucleic acid therapeutic agent to prepare a liposome encapsulating at least one non-nucleic acid therapeutic agent;
[0041] (c) preparing the pharmaceutical preparation by mixing the physical complex of the cationic material and at least one nucleic acid therapeutic agent with the liposomes encapsulating at least one non-nucleic acid therapeutic agent.
[0042] The pharmaceutical preparations prepared using the drug delivery carrier of the present invention can be administered, for example, through the oral cavity, nasal cavity, eye, respiratory tract, digestive tract, reproductive tract, local implantation, injection or infusion (via epidural, intra-arterial, intra-articular, intracapsular, intracardiac, intracerebroventricular, intracranial, intradermal, intramuscular, intraorbital, intraocular, intraperitoneal, intraspinal, intrasternal, intrathecal, intravenous, subarachnoid, subcapsular, subcutaneous, tracheal, rectal, sublingual and the like) for the treatment and / or prevention of diseases.
[0043] Unless otherwise limited, all technical and scientific terms used herein have the same meaning as those of ordinary skill in the art to which the present invention belongs. All publications, patent applications, patents and other references mentioned herein are fully incorporated herein by reference. In addition, the materials, methods and examples described herein are only illustrative and are not intended to be restrictive. Other features, purposes and advantages of the present invention will be apparent from this specification and the accompanying drawings and from the appended claims. BRIEF DESCRIPTION OF THE DRAWINGS
[0044] Figure 1 : Agarose gel electrophoresis results of cationic material / siRNA complex. The left side is agarose gel electrophoresis photos of different charge ratios of R8 (8-polyarginine) and siRNA (the numerical values in the figure represent the ratio of positive charge / negative charge), and the right side is agarose gel electrophoresis photos of different charge ratios of Penetratin and siRNA (the numerical values in the figure represent the ratio of positive charge / negative charge).
[0045] Figure 2: Agarose gel electrophoresis results of cationic material / siRNA complexes. The left side shows the agarose gel electrophoresis results of different charge ratios of CLS and siRNA (the numerical values in the figure represent the ratio of positive charge / negative charge), and the right side shows the agarose gel electrophoresis results of different charge ratios of PEI and siRNA (the numerical values in the figure represent the ratio of positive charge / negative charge).
[0046] Figure 3 : Agarose gel electrophoresis results of PAMAM and siRNA with different charge ratios (the numerical values in the figure represent the ratio of positive charge to negative charge).
[0047] Figure 4 : Particle size results of R8 and siRNA with different charge ratios (the numerical value of the abscissa in the figure represents the ratio of positive charge / negative charge).
[0048] Figure 5 : Potential results of different charge ratios between R8 and siRNA (the numerical value of the abscissa in the figure represents the ratio of positive charge / negative charge).
[0049] Figure 6 : Particle size results of penetratin and siRNA with different charge ratios (the numerical value of the abscissa in the figure represents the ratio of positive charge / negative charge).
[0050] Figure 7 : Potential results of different charge ratios of Penetratin and siRNA (the numerical value of the abscissa in the figure represents the ratio of positive charge / negative charge).
[0051] Figure 8 : Particle size results of different charge ratios of PEI and siRNA (the numerical value of the abscissa in the figure represents the ratio of positive charge / negative charge).
[0052] Fig. 9 : Potential results of different charge ratios of PEI and siRNA (the numerical value of the horizontal axis in the figure represents the ratio of positive charge / negative charge).
[0053] Fig.10 : Particle size results of different charge ratios of CLS and siRNA (the numerical value of the horizontal axis in the figure represents the ratio of positive charge / negative charge).
[0054] Fig.11 : Potential results of different charge ratios between CLS and siRNA (the numerical value of the abscissa in the figure represents the ratio of positive charge / negative charge).
[0055] Fig.12 : Particle size results of different charge ratios of PAMAM and siRNA (the numerical value of the abscissa in the figure represents the ratio of positive charge / negative charge).
[0056] Fig.13: Potential results of different charge ratios of PAMAM and siRNA (the numerical value of the abscissa in the figure represents the ratio of positive charge / negative charge).
[0057] Fig.14 : Particle size of CLS / cationic material / siRNA complex. Group 1: CLS / siRNA complex, CLS / PEI / siRNA liposome complex, PEI / siRNA complex; Group 2: CLS / siRNA complex, CLS / Penetratin / siRNA liposome complex, Penetratin / siRNA complex; Group 3: CLS / siRNA complex, CLS / PAMAM / siRNA liposome complex, PAMAM / siRNA complex.
[0058] Fig.15 : Particle size changes of CLS / cationic material / siRNA complex during placement.
[0059] Fig.16 : Shows the results of quantitative evaluation of cellular uptake of drug preparations with different proportions of membrane-penetrating peptides modified on the surface, among which the Lipo2000 group is a non-covalent complex of the commercially available gene transfection reagent cationic liposome Lipofectamine 2000 and siRNA.
[0060] Fig.17 : Shows the cellular uptake of drug preparations prepared using liposome membrane materials modified with cell-penetrating peptides of different formulations shown in Table 2 of Example 7.
[0061] Fig.18 : Shows the particle size of liposome drug preparations in which component (iv) accounts for 1%, 5%, 8%, and 10% by mole of the liposome membrane material modified with the cell-penetrating peptide.
[0062] Fig.19 : Shows the cellular uptake of CLS / R8 / siRNA liposome complexes prepared with different charge ratios of CLS to siRNA when the charge ratio of R8 to siRNA is 1:1.
[0063] Fig. 20 : Shows the qualitative and quantitative evaluation results of the transfection effect of different oligoarginine drug preparations on LUC-U87 cells.
[0064] Fig.21 : Shows the results of the evaluation of the apoptosis-promoting effect and cytotoxicity of the siRNA-encapsulated drug preparation on bEnd.3 cells and U87 cells.
[0065] Fig. 22 :Shows the half inhibitory concentration IC of each chemotherapy drug and gene drug50 Value determination results.
[0066] Fig.23 : Shows the in vitro anti-tumor pharmacodynamic evaluation results of gene drugs combined with different chemotherapy drugs.
[0067] Fig.24 : Shows the combination index and dose reduction index results of gene drugs combined with different chemotherapy drugs.
[0068] Fig.25 : Shows the results of in vitro anti-tumor pharmacodynamic screening of gene drugs combined with different chemotherapy drugs.
[0069] Fig.26 : Shows the in vitro antitumor pharmacodynamic results of the pharmaceutical preparation of the present invention, which is a combination of gene medicine and chemotherapy drug docetaxel (DTX).
[0070] Fig. 27 : Shows the results of FAM-siRNA encapsulated by a vector labeled with cell membrane fluorescent probe DiD and taken up by U87 cells and Calu-3 cells.
[0071] Fig.28 : The results of the evaluation of the apoptosis-promoting ability of the drug preparation of the present invention, which is a combination of gene drug and chemotherapy drug docetaxel (DTX), on U87 cells are shown.
[0072] Fig.29 : The pharmacodynamic evaluation results of the drug preparation of the present invention, which is a combination of gene drug and chemotherapy drug docetaxel (DTX), against U87 brain tumor in situ.
[0073] Fig.30 : Animal body weight curve in the pharmacodynamics experiment of the drug preparation of the present invention combining gene drug with chemotherapy drug docetaxel (DTX) against U87 brain in situ tumor. DETAILED DESCRIPTION OF THE INVENTION
[0074] The present invention provides a novel drug delivery carrier, which comprises cationic liposomes modified by penetratin and cationic materials, wherein the cationic materials are selected from positively charged polyamino acids, PEI, penetratin or derivatives of penetratin, and PAMAM. In the process of using the drug delivery carrier to prepare a pharmaceutical preparation comprising at least one non-nucleic acid therapeutic agent and at least one nucleic acid therapeutic agent, the cationic material contained in the drug delivery carrier is compressed once (compacted) to the nucleic acid therapeutic agent, and the cationic liposomes contained in the drug delivery carrier are compressed twice to the physical complex of the cationic material-at least one nucleic acid therapeutic agent, so that the particle size of the physical complex of the cationic material-at least one nucleic acid therapeutic agent is significantly reduced, the stability is significantly improved, and the penetratin with a membrane-penetrating function modified on the surface of the liposome helps the pharmaceutical preparation to penetrate the biomembrane barrier in the subject.
[0075] The drug delivery carrier of the present invention has a strong ability to carry multiple drugs, deliver multiple drugs and penetrate tissues, and has low tissue toxicity. It can efficiently deliver multiple drug molecules to the target site in the subject through multiple administration routes, overcome the technical problem that multiple drugs are difficult to reach the target site due to the biofilm barrier of the subject, enhance the effectiveness of the combined use of multiple drugs to treat diseases, and have good biosafety. Therefore, the present invention also provides a pharmaceutical preparation for co-delivering multiple therapeutic agents prepared using the drug delivery carrier.
[0076] Various features of the drug delivery vehicles of the present invention are discussed below.
[0077] As used herein, the term "about" is intended to be an adjustment of ±10% of the specified value. For example, the term "about 5%" is intended to include a range of 4.5% to 5.5%.
[0078] As used herein, the terms "comprising" or "including" are meant to include stated elements, integers or steps, but not to exclude any other elements, integers or steps.
[0079] As used herein, the term "cationic material" means a cationic material selected from positively charged polyamino acids, PEI, penetratin or a derivative of penetratin, and PAMAM.
[0080] I. Membrane materials of liposomes with surface modified with membrane-penetrating peptides:
[0081] As used herein, the term "liposome" refers to an artificially prepared vesicle composed of a lipid bilayer. The type of liposome modified by the cell-penetrating peptide in the present invention is not limited, and can be any liposome that can form lipid vesicles and encapsulate drugs.
[0082] As used herein, the term "lipid" refers to a hydrophobic or amphiphilic small molecule such as, but not limited to, a fatty acid, a phospholipid, a glyceride, a glycerophospholipid, a sphingolipid, a glycolipid, or a polyketide.
[0083] In some embodiments, the cationic liposomes modified with a membrane-penetrating peptide on the surface of the present invention comprise the following membrane materials:
[0084] (i) Cationic lipids:
[0085] Liposomes include one or more cationic lipids. As used herein, the term "cationic lipid" is a lipid with a net positive charge at a selected pH (e.g., physiological pH). Many cationic lipids are commercially available. Particularly suitable cationic lipids for use in liposomes include those described in International Patent Publications WO 2010 / 053572 and WO 2012 / 170930, both of which are incorporated herein by reference.
[0086] There is no particular limitation on the cationic lipids included in the liposomes, as long as they are lipids with a net positive charge at a selected pH (e.g., physiological pH), such as, but not limited to: 1,2-di-O-octadecenyl-3-trimethylammonium propane (DOTMA); dimethyldioctadecyl ammonium (DDAB); 1,2-dioleoyl-3-trimethylammonium-propane (DOTAP); 1,2-dioleoyl-3-dimethylammonium-propane (DODAP); 1,2-diacyloxy-3-dimethylammonium propane; 1,2-dialkoxy-3-dimethylammonium propane; dioctadecyl dimethyl ammonium chloride (DODAC), 1,2-dimyristoyloxypropyl-1,3-dimethylhydroxyethylammonium (DMRIE) and 2,3-dioleoyloxy-N-[2(sperminecarboxamide)ethyl]-N,N-dimethyl-1-propane trifluoroacetate ammonium (DOSPA) and combinations thereof. Preferred cationic lipids are DOTMA, DOTAP, DODAC and DOSPA. The most preferred cationic lipid is DOTAP.
[0087] (ii) Non-cationic lipids:
[0088] Liposomes include one or more non-cationic lipids. As used herein, the term "non-cationic lipid" refers to any neutral, zwitterionic or anionic lipid. As used herein, the term "anionic lipid" refers to any of the many lipid species that carry a net negative charge at a selected pH, such as a physiological pH.
[0089] There is no particular limitation on the non-cationic lipids contained in the liposomes, and any neutral, zwitterionic or anionic lipids can be used, such as but not limited to: 1,2-di-(9Z-octadecanoyl)-sn-glycero-3-phosphoethanolamine (DOPE), 1,2-dioleoyl-sn-glycero-3-phosphocholine (DOPC), 1,2-distearoyl-sn-glycero-3-phosphocholine (DSPC), 1,2-dipalmitoyl-sn-glycero-3-phosphocholine (DPPC), 1,2-dipalmitoyl-sn-glycero-3-phosphoethanolamine (DPPE), 1,2-dimyristoyl-sn-glycero-3-phosphoethanolamine (DMPE), 2-dioleoyl-sn-glycero-3-phospho-(1'-rac-glycerol) (DOPG) and combinations thereof. Preferred non-cationic lipids are DOPE and / or DOPC. The most preferred non-cationic lipid is DOPE.
[0090] (iii) Cholesterol:
[0091] Cholesterol is an important component of mammalian cell membranes, accounting for more than 20% of cell membrane lipids. The term "cholesterol" is used in the broadest sense in this article and covers cholesterol derivatives. Studies have shown that at high temperatures, cholesterol can prevent the disorder of the cell membrane bilayer; at low temperatures, cholesterol can interfere with the order of the cell membrane bilayer and prevent liquid crystal The formation of bilayer membranes maintains the fluidity of the cell membrane.
[0092] Considering the importance of cholesterol in the bilayer of the liposome membrane, the cationic liposome of the present invention also contains cholesterol.
[0093] (iv) PEGylated phospholipids and polyethylene glycol phospholipids conjugated with CPP
[0094] The liposomes comprise PEGylated phospholipids and polyethylene glycol phospholipids conjugated with CPP. Herein, the PEGylated phospholipids do not comprise polyethylene glycol phospholipids linked to CPP.
[0095] PEGylated phospholipids are formed by covalently bonding phospholipids to one or more polyethylene glycol molecules (PEG). PEGylated phospholipids include, but are not limited to, polyethylene glycol chains up to 10 kDa in length, for example, 1 kDa, 2 kDa, 3 kDa, 4 kDa, 5 kDa, 6 kDa, 7 kDa, 8 kDa, 9 kDa, 10 kDa, and any value therebetween, which are covalently bonded to phospholipids. The phospholipids may be synthetic, semi-synthetic or natural phospholipids, for example, phosphatidylcholine, phosphatidylethanolamine, phosphatidylinositol and sphingomyelin. In some embodiments, the PEGylated phospholipids are, for example, polyethylene glycol-distearoylphosphatidylethanolamine (PEG-DSPE) and its derivatives methoxy-polyethylene glycol-distearoylphosphatidylethanolamine (mPEG-DSPE), wherein the molecular weight of PEG is any value between 1 kDa and 10 kDa.
[0096] The polyethylene glycol phospholipid conjugated with CPP is formed by covalently bonding CPP to polyethylene glycol phospholipid.
[0097] The CPP used in the present invention includes not only the wild-type polypeptide penetratin (amino acid sequence: RQIKIWFQNRRMKWKK (SEQ ID NO: 2)), but also a series of lipophilic derivatives thereof, for example, the 2nd glutamine (Q) and / or the 8th glutamine (Q) and / or the 9th asparagine (N) of penetratin are mutated to hydrophobic amino acids. In some embodiments, the lipophilic derivatives of penetratin are those disclosed in the Chinese invention patent application CN201710414334.7, which have been proven to promote the drug to pass through many ocular absorption barriers (cornea, conjunctiva, sclera, etc.) into the eye after administration by eye drops in the conjunctival sac, and even deliver the biomacromolecule drugs such as genes, polypeptides and proteins carried by them to the retinal part of the posterior segment of the eye. The amino acid sequence of the lipophilic derivative of penetratin disclosed in the Chinese invention patent application CN201710414334.7 is cited here as follows:
[0098] Table 1: Amino acid sequences of Penetratin derivatives
[0099]
[0100]
[0101] According to the present invention, CPP is a compound that is attached as part of the lipid bilayer of the liposome by covalent bonding to polyethylene glycol phospholipids. In this article, the term "as part of the lipid bilayer of the liposome" is intended to indicate the fact that the phospholipid in CPP-PEG-phospholipid is integrated into the lipid bilayer. The phospholipid can be a synthetic, semi-synthetic or natural phospholipid, for example, phosphatidylcholine, phosphatidylethanolamine, phosphatidylinositol and sphingomyelin.
[0102] The polyethylene glycol chain in CPP-PEG-phospholipid includes but is not limited to a polyethylene glycol chain with a length of up to 10kDa, for example, 1kDa, 2kDa, 3kDa, 4kDa, 5kDa, 6kDa, 7kDa, 8kDa, 9kDa, 10kDa, and any value therebetween, with its two ends covalently bonded to the phospholipid and the CPP, respectively. In some embodiments, the polyethylene glycol phospholipid conjugated to CPP is, for example, Penetratin / Penetratin derivative-PEG-DSPE, wherein the molecular weight of PEG is any value between 1kDa and 10kDa.
[0103] The present invention modifies CPP on the surface of cationic liposomes to enhance the penetration ability of drug delivery carriers in tissues, thereby helping liposomes carrying multiple drug molecules to reach target sites, thereby exerting a therapeutic and / or preventive effect on diseases.
[0104] In some embodiments, the polyethylene glycol chain lengths of the PEGylated phospholipids and the polyethylene glycol phospholipids conjugated to the CPP in the cell-penetrating peptide-modified liposome membrane material (iv) are not equal, and the polyethylene glycol chain in the polyethylene glycol phospholipids conjugated to the CPP is longer than the polyethylene glycol chain in the PEGylated phospholipids, for example, longer by 0.5 kDa to 5 kDa, preferably longer by 0.75 kDa to 4 kDa, and more preferably longer by any value between 1 kDa and 2 kDa. In one embodiment, the polyethylene glycol chain lengths of the PEGylated phospholipids in the cell-penetrating peptide-modified liposome membrane material (iv) are about 1 kDa, 2 kDa, and 3 kDa, respectively, and the polyethylene glycol chain lengths of the polyethylene glycol phospholipids conjugated to the CPP are about 2.5 kDa, 3.5 kDa, and 4.5 kDa, respectively.
[0105] In some embodiments, the molar ratio of the membrane material (i): (ii): (iii): (iv) of the cationic liposomes modified with a cell-penetrating peptide on the surface of the present invention is about 20-40: 20-40: 20-40: 1-20, and the polyethylene glycol phospholipid conjugated with CPP accounts for about 20%-80% of the molar ratio of the membrane material (iv), corresponding to about 2%-8% of the total cell-penetrating peptide-modified liposome membrane material. In some embodiments, the molar ratio of the membrane material (i): (ii): (iii): (iv) is about 27.0-31.6: 27.0-31.6: 31.6-39.6: 1-10, and the polyethylene glycol phospholipid conjugated with CPP accounts for about 20%-80% of the molar ratio of the membrane material (iv), corresponding to about 2%-8% of the total cell-penetrating peptide-modified liposome membrane material.
[0106] In some specific embodiments, the cationic liposomes in the drug delivery carrier of the present invention comprise the following membrane materials: (i) DOTAP; (ii) DOPE; (iii) cholesterol; (iv) PEG-DSPE (e.g., mPEG 2000 -DSPE) and Penetratin / Penetratin derivative-PEG-DSPE (e.g., 89W Penetratin-PEG 3400 -DSPE), and the molar ratio of membrane materials (i):(ii):(iii):(iv) is about 20-40:20-40:20-40:1-20, and Penetratin / Penetratin derivative-PEG-DSPE (e.g., 89W Penetratin-PEG 3400 -DSPE) accounts for about 20% to 80% molar ratio in the membrane material (iv). In some embodiments, the molar ratio of membrane material (i): (ii): (iii): (iv) is about 27.0-31.6: 27.0-31.6: 31.6-39.6: 1-10, and Penetratin / Penetratin derivative-PEG-DSPE (e.g., 89W Penetratin-PEG 3400 -DSPE) accounts for about 20% to 80% molar ratio in the membrane material (iv). In some embodiments, the cationic liposomes in the drug delivery carrier of the present invention are composed of the following membrane materials: (i) DOTAP; (ii) DOPE; (iii) cholesterol; (iv) mPEG 2000 -DSPE and 89W Penetratin-PEG 3400-DSPE, and the molar ratio of membrane materials (i):(ii):(iii):(iv) is about 28.5:28.5:38:5, 89W Penetratin-PEG 3400 - DSPE accounts for about 20%, 25%, 30%, 35%, 40%, 45%, 50%, 55%, 60%, 65%, 70%, 75%, 80% by mole in the membrane material (iv).
[0107] II. Cationic Materials
[0108] The cationic material contained in the drug delivery carrier of the present invention is used for compressing the nucleic acid therapeutic agent. The cationic material is selected from positively charged polyamino acids, polyethyleneimine (PEI), penetratin or a derivative of penetratin, and polyamidoamine (PAMAM).
[0109] In some embodiments, the cationic material is a positively charged polyamino acid, which is a polyamino acid with a net positive charge at a selected pH (e.g., physiological pH). There is no particular restriction on the degree of polymerization of the amino acid residues in the polyamino acid, such as a positively charged polyamino acid with a degree of polymerization of 2-50 (i.e., a positively charged polyamino acid having 2-50 amino acid residues), such as arginine and / or lysine with a degree of polymerization of 6-12, and optionally 1-20 (e.g., 1-6) uncharged amino acid residues under physiological conditions are inserted in the middle of the positively charged polyamino acid with a degree of polymerization of 2-50. The positively charged polyamino acid can be linear or cyclic, and the configuration of the amino acid residues includes L-type and D-type. Preferably, the positively charged polyamino acid is a polyarginine with a degree of polymerization of 6-12, wherein the spatial structure of the polyarginine includes linear and cyclic, and the configuration of the polyarginine includes L-type and D-type.
[0110] In some embodiments, the positively charged polyamino acid is an oligo-arginine, including linear polypeptides such as 6-arginine (amino acid sequence is RRRRRR, R6 (SEQ ID NO: 85)), 8-arginine (amino acid sequence is RRRRRRRR, R8 (SEQ ID NO: 86)), 10-arginine (amino acid sequence is RRRRRRRRRR, R10 (SEQ ID NO: 87)), 12-arginine (amino acid sequence is RRRRRRRRRRRR, R12 (SEQ ID NO: 88)). NO:88)), as well as cyclized polypeptides, such as cyclized 6-polyarginine (c-R6), cyclized 8-polyarginine (c-R8), cyclized 10-polyarginine (c-R10), cyclized 12-polyarginine (c-R12), and polypeptides of different configurations, such as L-type oligoarginine and D-type oligoarginine such as 6-poly D-arginine (amino acid sequence is rrrrrr, D-R6), 8-poly D-arginine (amino acid sequence is rrrrrrrr, D-R8), 10-poly D-arginine (amino acid sequence is rrrrrrrrrr, D-R10), and 12-poly D-arginine (amino acid sequence is rrrrrrrrrrrr, D-R12).
[0111] The following describes a method for preparing a pharmaceutical preparation for co-delivering multiple therapeutic agents using the drug delivery carrier of the present invention, and describes the characteristics of the pharmaceutical preparation.
[0112] By using the drug delivery carrier of the present invention, it is possible to prepare a drug preparation in which CPP is modified on the surface of a cationic liposome and has a strong penetrating ability in tissues and is capable of co-delivering multiple therapeutic agents.
[0113] In one embodiment, the preparation method of the pharmaceutical preparation of the present invention is:
[0114] (1) Weighing the above-mentioned liposome membrane material of the present invention, wherein the molar ratio of membrane material (i): (ii): (iii): (iv) is about 20-40: 20-40: 20-40: 1-20, and the polyethylene glycol phospholipid conjugated with CPP accounts for about 20%-80% of the molar ratio in the membrane material (iv), corresponding to about 2%-8% of the molar ratio in the total membrane material of the cell-penetrating peptide-modified liposome, and at least one non-nucleic acid therapeutic agent.
[0115] (2) adding membrane materials (i):(ii):(iii):(iv) and at least one non-nucleic acid therapeutic agent to an organic solvent for dissolution, and then evaporating the organic solvent to obtain a uniform dry lipid film.
[0116] (3) After the obtained dried lipid film is completely hydrated with an aqueous solution, the liposomes are extruded using a micro extruder (the order of passing through the nuclear pore membrane is 200 nm, 100 nm and 50 nm).
[0117] (4) Mixing a cationic material (eg, a positively charged polyamino acid, PEI, penetratin or a penetratin derivative, PAMAM) with at least one nucleic acid therapeutic agent in a suitable solution and incubating the mixture to obtain a physical complex of the cationic material and at least one nucleic acid therapeutic agent.
[0118] (5) mixing the liposomes obtained in (3) and the physical complex of the cationic material and at least one nucleic acid therapeutic agent obtained in (4) at a certain molar ratio or charge ratio to obtain a pharmaceutical preparation in the form of a liposome complex containing at least one non-nucleic acid therapeutic agent and at least one nucleic acid therapeutic agent.
[0119] In another embodiment, the preparation method of the pharmaceutical preparation of the present invention is:
[0120] (1) Weighing the above-mentioned liposome membrane material of the present invention, wherein the molar ratio of membrane material (i): (ii): (iii): (iv) is about 20-40: 20-40: 20-40: 20-40: 1-20, and the polyethylene glycol phospholipid conjugated with CPP accounts for about 20%-80% of the molar ratio in the membrane material (iv), corresponding to about 2%-8% of the molar ratio in the total membrane material of the cell-penetrating peptide-modified liposome.
[0121] (2) adding membrane materials (i): (ii): (iii) and at least one non-nucleic acid therapeutic agent to an organic solvent for dissolution, and then evaporating the organic solvent to obtain a uniform dry lipid film.
[0122] (3) After the obtained dried lipid film is completely hydrated with an aqueous solution, the liposomes are extruded using a micro extruder (the order of passing through the nuclear pore membrane is 200 nm, 100 nm and 50 nm).
[0123] (4) Mixing a cationic material (eg, a positively charged polyamino acid, PEI, penetratin or a penetratin derivative, PAMAM) with at least one nucleic acid therapeutic agent in a suitable solution and incubating the mixture to obtain a physical complex of the cationic material and at least one nucleic acid therapeutic agent.
[0124] (5) The liposomes obtained in (3) and the physical complex of the cationic material and at least one nucleic acid therapeutic agent obtained in (4) are mixed at a certain molar ratio or charge ratio, and then mixed and incubated with the membrane material (iv) to obtain the pharmaceutical preparation of the present invention.
[0125] The at least one non-nucleic acid therapeutic agent to be delivered is not particularly limited and includes a wide range of compounds delivered to a subject, including, but not limited to: anti-infectives such as antibiotics and antivirals; analgesics and analgesic combinations; appetite suppressants; anthelmintics; antiarthritics; antiasthmatics; anticonvulsants; antidepressants; antidiabetics; antidiabetics; antidiarrheals; antihistamines; anti-inflammatory drugs; anti-migraine preparations; antinauseants; antineoplastics; antiparkinsonians; antipruritics; antipsychotics; antipyretics; antispasmodics; anticholinergics; sympathomimetics Drugs; xanthine derivatives; cardiovascular preparations including potassium channel blockers, calcium channel blockers, beta-blockers, alpha-blockers and antiarrhythmic drugs; antihypertensive drugs; diuretics and antidiuretics; vasodilators including stimulants of systemic nerves, cardiac nerves, peripheral nerves and cranial nerves, central nervous system, vasopressors; cough and cold preparations including decongestants; hormones such as estradiol and other steroids, including corticosteroids; hypnotic drugs; immunosuppressive drugs; muscle relaxants; parasympathetic nerve blockers; psychostimulants; sedatives and tranquilizers. The drug delivery carrier of the present invention can deliver drugs in all forms such as ionized, non-ionized, free base, acid addition salts, etc., and can deliver high molecular weight or low molecular weight drugs.
[0126] There is no particular limitation on the at least one nucleic acid therapeutic agent to be delivered, including but not limited to plasmid DNA, RNA such as small interfering RNA (siRNA), miRNA, sense RNA, antisense oligonucleotides (ASO), aptamers, ribozymes and the like. For example, the nucleic acid therapeutic agent is an RNA targeting brain diseases such as brain tumors (e.g., gliomas), such as siRNA targeting c-myc.
[0127] The pharmaceutical preparations of the present invention can be administered through the oral cavity, nasal cavity, eye, respiratory tract, digestive tract, reproductive tract, local implantation, injection or infusion (via epidural, intra-arterial, intra-articular, intracapsular, intracardiac, intracerebroventricular, intracranial, intradermal, intramuscular, intraorbital, intraocular, intraperitoneal, intraspinal, intrasternal, intrathecal, intravenous, subarachnoid, subcapsular, subcutaneous, tracheal, rectal, sublingual, etc.).
[0128] The pharmaceutical preparations of the present invention may be administered using medical devices known in the art. For example, in one embodiment, the pharmaceutical preparations of the present invention may be administered using a needle-free hypodermic injection device, such as the device disclosed in US Pat. No. 5,399,163.
[0129] In one embodiment, the drug delivery vector of the present invention is used to prepare a drug preparation for co-delivering a chemotherapeutic drug and a nucleic acid drug siRNA, thereby exerting a synergistic effect in treating cancer.
[0130] Chemotherapy remains one of the most commonly used cancer treatments. However, because chemotherapy drugs actively target dividing cells (a characteristic of cancer cells), healthy dividing cells such as blood cells, as well as cells in the intestines, mouth and hair are also affected, and chemotherapy drugs can have strong side effects. Scientists have been working to improve the administration and combination of chemotherapy drugs to minimize these side effects.
[0131] In addition, nucleic acid therapeutic agents have attracted great attention in the use of treating diseases (e.g., cancer). Although they have potential in cancer treatment, nucleic acid therapeutic agents may be easily attacked and degraded by enzymes prevalent in the environment, and nucleic acids themselves cannot enter cells, and existing delivery systems only have low delivery efficiency.
[0132] The drug delivery carrier of the present invention can minimize the side effects of chemotherapeutic drugs and efficiently allow nucleic acid therapeutic agents to enter cells, and the nucleic acid therapeutic agents are not easily attacked by enzymes commonly present in the environment.
[0133] In one embodiment, the pharmaceutical preparation of the present invention for co-delivering chemotherapeutic drugs and nucleic acid drug siRNA is administered nasally, and the chemotherapeutic drugs and nucleic acid drug siRNA are efficiently delivered into the brain via the nose-brain pathway. After being taken up by brain tumor cells, the chemotherapeutic drugs and nucleic acid drug siRNA can achieve endosomal escape with the help of transmembrane peptides and the surface positive charges of cationic liposomes, and release the chemotherapeutic drugs and nucleic acid drug siRNA into the cytoplasm, thereby exerting the effects of chemical killing and gene therapy of brain tumors (e.g., glioma).
[0134] It is well known to those skilled in the art that the special physiological structure and functional complexity of the brain, especially the presence of the blood-brain barrier and the physicochemical properties of some drugs themselves, make it difficult for therapeutic drugs to reach brain tissue. However, the route of administration of drugs into the brain through the nose provides a feasible idea for the treatment of brain diseases. There are two direct pathways for drugs to enter the brain through the nasal cavity, one of which is the olfactory nerve pathway, which is the most direct method for bypassing the blood-brain barrier through the nose. The drug is absorbed through the nasal mucosa, and after being taken up by the olfactory nerve, it is transported to the olfactory bulb by axons, and further arrives at the process of the olfactory brain. The second is the nasal mucosal epithelial pathway, and the drug passes through the basement membrane into the lamina propria, further reaches the peripheral olfactory nerve, and then is transported to the central nervous system, and finally achieves accumulation in the brain. Because the administration of drugs into the brain through the nose is non-invasive, the patient's compliance is good (Agrawal M et al., Nose-to-brain drug delivery:An update on clinical challenges and progress towardsapproval of anti-Alzheimer drugs, Journal of Controlled Release, 2018, 281:139-177). On the other hand, brain tumors such as glioma are malignant tumors of the central nervous system with a high incidence rate and low survival rate, which poses a great threat to human health. However, the clinical prognosis is not optimistic, which is mainly reflected in surgical recurrence, chemotherapy resistance, etc. In addition, due to the existence of the blood-brain barrier and the blood-brain tumor barrier, the amount of drugs entering the brain after systemic administration is very small. Therefore, people have been committed to finding an effective drug treatment method.
[0135] After nasal administration, the pharmaceutical preparation for co-delivering chemotherapeutic drugs and nucleic acid drug siRNA of the present invention can simultaneously deliver the chemotherapeutic drugs and nucleic acid drug siRNA to the brain, and synergistically exert a therapeutic effect on brain tumors. In addition, since the drug can be delivered into the brain through the nasal administration route, the pharmaceutical preparation of the present invention is conducive to improving patient compliance.
[0136] The following examples are described to assist understanding of the present invention. The examples are not intended to and should not be interpreted in any way as limiting the scope of protection of the present invention. Example
[0137] Example 1. Preparation of cationic liposomes
[0138] The membrane materials with a molar ratio of 28.5:28.5:38:5 were weighed, namely 3.5 mg of DOTAP (Shanghai Avite Pharmaceutical Technology Co., Ltd., 132172-61-3), 3.72 mg of DOPE (Shanghai Avite Pharmaceutical Technology Co., Ltd., 4004-05-1), 2.59 mg of cholesterol (Sigma-Aldrich, C8667) and 2.46 mg of mPEG. 2000 -DSPE (Shanghai Avite Pharmaceutical Technology Co., Ltd., 147867-65-0).
[0139] The amount of DOTAP, DOPE and cholesterol was placed in a 50 mL round-bottom flask, 1 mL of chloroform was added to dissolve the DOTAP, DOPE and cholesterol as lipid membrane materials, that is, 16.67 μmol of CLS contained 5 μmol of DOTAP, 5 μmol of DOPE and 6.67 μmol of cholesterol, and the resulting solution was passed through a rotary evaporator (Shanghai Shensheng Technology Co., Ltd., R201L) to remove the chloroform to obtain a uniform dry lipid film.
[0140] The obtained dried lipid film was hydrated with 1 mL of 5% glucose aqueous solution by ultrasonic hydration in a 37°C water bath for about 10 minutes. After the lipid film was completely hydrated, a micro extruder (Hamilton, 81320) was used to extrude the liposomes (the order of passing through the nuclear pore membrane was 200 nm, 100 nm, and 50 nm), and cationic liposomes (also referred to as CLS in this article) without modification of the membrane-penetrating peptide were obtained.
[0141] The prepared cationic liposomes were mixed with 2.46 mg of mPEG 2000 -DSPE (dissolved in water) was mixed and incubated at 55°C for half an hour to obtain mPEG 2000 -Cationic liposomes of DSPE.
[0142] Example 2. Compression effect of cationic materials on gene drugs
[0143] Agarose gel electrophoresis experiments are commonly used to measure the entrapment capacity of cationic materials contained in drug delivery carriers for drugs such as nucleic acids. In the present embodiment, R8 / siRNA complex, Penetratin / siRNA complex, CLS / siRNA complex, PEI / siRNA complex, PAMAM / siRNA complex were prepared, and the entrapment capacity of R8, Penetratin, CLS, polyethyleneimine (Polyethylenlmlne, PEI, molecular weight is 25000) and 3 generations of polyamide-amine (PAMAM) for nucleic acids was determined respectively by agarose gel electrophoresis experiments.
[0144] 33 μg of siRNA (in this example, small interfering RNA against c-myc, hereinafter abbreviated as siRNA, whose sense strand (5'-3') is AACGUUAGCUUCACCAACAdTdT (SEQ ID NO: 79), and antisense strand (5'-3') is UGUUGGUGAAGCUAACGUUdTdT (SEQ ID NO: 80)) was dissolved in 125 μL of DEPC-treated water to prepare a 20 μM siRNA solution.
[0145] Oligoarginine R8 (Shanghai Xinhao Biotechnology Co., Ltd.), Penetratin (Shanghai Xinhao Biotechnology Co., Ltd.), CLS prepared in Example 1, PEI (Sigma-Aldrich (Shanghai) Trading Co., Ltd.), and PAMAM (Weihai Chenyuan Molecular New Materials Co., Ltd.) were dissolved in pure water, mixed with siRNA at a certain charge ratio, vortexed for 30 seconds, and incubated at 37°C for 30 minutes to obtain R8 / siRNA complex, Penetratin / siRNA complex, CLS / siRNA complex, PEI / siRNA complex, and PAMAM / siRNA complex.
[0146] The R8 / siRNA complex, Penetratin / siRNA complex, CLS / siRNA complex, PEI / siRNA complex, and PAMAM / siRNA complex prepared above were carefully added to the agarose gel sample wells, and a free siRNA control group was set up for electrophoresis. After the electrophoresis, the gel was stained with GelRed working solution (Biotium Inc.) for 30 minutes in the dark, and the gel was imaged under ultraviolet wavelength of 302nm. The results are shown in Figure 1 - Figure 3 shown.
[0147] The R8 / siRNA complex, Penetratin / siRNA complex, CLS / siRNA complex, PEI / siRNA complex, and PAMAM / siRNA complex prepared above were subjected to particle size measurement and zeta potential measurement. The particle size was directly measured using dynamic light scattering technology. The zeta potential was measured in water at 23°C using a zeta potential analyzer with an electric field strength of 5V / cm and an electrode spacing of 0.4cm. The results are shown in Figure 4 - Fig.13 shown.
[0148] Since one amino nitrogen of R8 carries a positive charge and one phosphate group of siRNA carries a negative charge, 1 μM of R8 contains 8 μM of amino nitrogen, that is, 1 μM of R8 contains 8 μM of positive charge, and 1 μM of siRNA contains 42 μM of phosphate, that is, 1 μM of siRNA contains 42 μM of negative charge. The charge ratio of R8 to siRNA = (μM value of R8 × 8) / (μM value of siRNA × 42) = 0.19 × R8 (μM) / siRNA (μM).
[0149] Since one amino nitrogen of Penetratin carries a positive charge and one phosphate group of siRNA carries a negative charge, 1 μM of Penetratin contains 7 μM of amino nitrogen, that is, 1 μM of Penetratin contains 7 μM of positive charge, and 1 μM of siRNA contains 42 μM of phosphate, that is, 1 μM of siRNA contains 42 μM of negative charge. The charge ratio of Penetratin to siRNA = (μM value of Penetratin × 7) / (μM value of siRNA × 42) = 0.17 × Penetratin (μM) / siRNA (μM).
[0150] Since one amino nitrogen of DOTAP carries a positive charge and one phosphate group of siRNA carries a negative charge, 16.67 μM CLS contains 5 μM DOTAP, that is, 1 μM CLS contains 0.3 μM positive charge and 1 μM siRNA contains 42 μM negative charge. The charge ratio of CLS to siRNA = (μM value of CLS × 0.3) / (μM value of siRNA × 42) = 0.007 × CLS (μM) / siRNA (μM).
[0151] Since one amino nitrogen of PEI carries a positive charge, every two carbon atoms in its repeating structure monomer are connected to primary and secondary amines containing nitrogen atoms, that is, one N atom corresponds to every 43 molecular weights of PEI, and one phosphate group of siRNA carries a negative charge. The average molecular weight of siRNA is 13300, and 1M siRNA contains 42M phosphate groups, that is, one phosphate corresponds to every 317 molecular weights of siRNA. The charge ratio of PEI to siRNA = (mass of PEI in mg) / (mass of siRNA in mg) × (317 / 43) = 7.37 × PEI (mg) / siRNA (mg).
[0152] Since one amino nitrogen of PAMAM carries a positive charge and one phosphate group of siRNA carries a negative charge, according to the formula in the literature, the charge ratio of PAMAM to siRNA = 1.53×PAMAM (mg) / siRNA (mg).
[0153] Example 3. Particle size and potential characterization after secondary compression using cationic liposomes
[0154] The Penetratin / siRNA complex, PEI / siRNA complex and PAMAM / siRNA complex prepared in Example 2 were used to prepare liposome complexes with CLS. Specifically, 8 μL of the Penetratin / siRNA complex, PEI / siRNA complex and PAMAM / siRNA complex were mixed with 2.67 μL of 16.67 μM cationic liposome CLS prepared in Example 1, vortexed for 30 seconds, and incubated at 37° C. for 30 minutes to obtain liposome complexes CLS / Penetratin / siRNA, CLS / PEI / siRNA and CLS / PAMAM / siRNA. In the liposome complexes CLS / Penetratin / siRNA, CLS / PEI / siRNA and CLS / PAMAM / siRNA, based on the charge number of siRNA, the charge ratio of cationic liposome CLS to siRNA is fixed at 4 (because one amino nitrogen of DOTAP carries a positive charge and one phosphate group of siRNA carries a negative charge, 16.67 μM CLS contains 5 μM DOTAP, that is, 1 μM CLS contains 0.3 μM positive charge and 1 μM siRNA contains 42 μM negative charge, and the charge ratio of CLS to siRNA = (μM value of CLS × 0.3) / (μM value of siRNA × 42) = 0.007 × CLS (μM) / siRNA (μM)).
[0155] The particle sizes of the liposome complexes CLS / Penetratin / siRNA, CLS / PEI / siRNA and CLS / PAMAM / siRNA prepared above were measured respectively, and the changes in the particle sizes of the liposome complexes during storage were observed. Fig.14 and Fig.15 .
[0156] The results showed that in the process of preparing CLS / cationic material / siRNA liposome complexes, after secondary compression of CLS, the particle size was significantly reduced compared with the simple CLS / siRNA complex and cationic material / siRNA complex. Therefore, CLS / cationic material / siRNA liposome complexes are more stable than simple CLS / siRNA complexes and cationic material / siRNA complexes, can provide better protection for siRNA and drugs, and are more conducive to delivering siRNA and drugs to deep tissues of lesions.
[0157] Example 4. Preparation of cationic liposomes and cationic materials encapsulating gene drugs
[0158] 4 mg of positively charged polyamino acid, oligoarginine R8 (Shanghai Xinhao Biotechnology Co., Ltd.) as a cationic material was dissolved in DEPC-treated water (Dalian Meilun Biotechnology Co., Ltd., MA0018) to prepare a 4 mg / mL oligoarginine R8 solution, and 33 μg of siRNA (in this example, small interfering RNA against c-myc was used, also abbreviated as siRNA in the following examples, whose sense strand (5'-3') is AACGUUAGCUUCACCAACAdTdT (SEQ ID NO: 79), and antisense strand (5'-3') is UGUUGGUGAAGCUAACGUUdTdT (SEQ ID NO: 80)) was dissolved in 125 μL of DEPC-treated water to prepare a 20 μM siRNA solution.
[0159] The oligoarginine R8 solution and the siRNA solution were mixed in equal volumes at a charge ratio of 5 (since one amino nitrogen of R8 carries a positive charge and one phosphate group of siRNA carries a negative charge, 1 μM R8 contains 8 μM amino nitrogen, i.e., 1 μM R8 contains 8 μM positive charge, 1 μM siRNA contains 42 μM phosphate group, i.e., 1 μM siRNA contains 42 μM negative charge, the charge ratio of R8 to siRNA = (μM value of R8 × 8) / (μM value of siRNA × 42) = 0.19 × R8 (μM) / siRNA (μM)), vortexed for 30 seconds, and incubated at 37°C for 30 minutes to obtain the R8 / siRNA complex.
[0160] The CLS / R8 / siRNA lipoplex was prepared by mixing the R8 / siRNA complex prepared above with CLS. Specifically, 8 μL of the R8 / siRNA complex (i.e., prepared from 4 μL of siRNA solution and 4 μL of R8 solution) was mixed with 2.67 μL of 16.67 μM cationic liposome CLS prepared in Example 1, vortexed for 30 seconds, and incubated at 37° C. for 30 minutes to obtain the lipoplex CLS / R8 / siRNA. In the lipid complex CLS / R8 / siRNA, based on the charge number of siRNA, the charge ratio of cationic liposome CLS to siRNA is fixed at 4 (since one amino nitrogen of DOTAP carries a positive charge and one phosphate group of siRNA carries a negative charge, 16.67 μM CLS contains 5 μM DOTAP, that is, 1 μM CLS contains 0.3 μM positive charge and 1 μM siRNA contains 42 μM negative charge, and the charge ratio of CLS to siRNA = (μM value of CLS × 0.3) / (μM value of siRNA × 42) = 0.007 × CLS (μM) / siRNA (μM)).
[0161] Similarly, a FAM-siRNA solution in which carboxyfluorescein (FAM) was modified at the 5' end of the sense strand of the siRNA and a CLS / R8 / FAM-siRNA complex were prepared.
[0162] Example 5. Preparation of surface-modified liposome drug formulations
[0163] The liposome drug preparation is surface-modified using a cell-penetrating peptide to obtain a surface-modified drug preparation.
[0164] i. Preparation of cell-penetrating peptide-PEG-phospholipid:
[0165] DSPE-polyethylene glycol maleimide (DSPE-PEG 3400 -maleimide) (Laysan Bio, 146-123) and a penetratin derivative modified with cysteine at the end ( 89W Penetratin-Cys) was prepared by one-step reaction to obtain the cell-penetrating peptide-PEG-DSPE.
[0166] Specifically, 20 mg DSPE-PEG 3400 -Maleimide was dissolved in 1 mL of N,N-dimethylformamide, and 18 mg of 2-(2-hydroxy-2-nitropropene) dissolved in 10 mL of phosphate buffer (10 mM, pH 7.2) was added to the solution under stirring. 89W Penetratin-Cys was stirred overnight at 25°C to complete the reaction. After the reaction was completed, the resulting mixture was dialyzed in pure water for 2 days under ice bath conditions and freeze-dried to obtain a white flocculent. 89W Penetratin-PEG 3400 -DSPE.
[0167] Wherein, the polypeptide 89W Penetratin is a derivative of penetratin, and its specific amino acid sequence is RQIKIWFWWRRMKWKK (89W in the text indicates the product of tryptophan mutation of glutamine at position 8 and asparagine at position 9 of penetratin). The penetratin in penetratin-PEG-DSPE can also use other penetratin derivatives, for details, please refer to Chinese invention patent application CN201710414334.7.
[0168] To facilitate the reaction with the polyethylene glycol terminal group, the cell-penetrating peptide 89W A cysteine residue (C) may be additionally added to the N-terminus or C-terminus of penetratin or other penetratin derivatives.
[0169] ii. Preparation of surface modified liposome drug preparations:
[0170] For 5% mPEG in the total molar number of cell-penetrating peptide-modified liposomes 2000 -DSPE and 89W Penetratin-PEG 3400 -DSPE, respectively formulated 89W Penetratin-PEG 3400 -The molar number of DSPE in mPEG 2000 -DSPE and 89W Penetratin-PEG 3400 -A mixture of 0%, 20%, 40%, 60%, 80%, and 100% molar amounts of DSPE. 89W Penetratin-PEG 3400 The molar number of -DSPE accounts for 0%, 1%, 2%, 3%, 4% and 5% of the total molar number of the liposome membrane material modified by the cell-penetrating peptide, respectively.
[0171] The CLS / R8 / FAM-siRNA complex prepared in Example 4 was 89W Penetratin-PEG 3400 -The molar number of DSPE in mPEG 2000 -DSPE and 89W Penetratin-PEG 3400 -DSPE with a molar number of 0%, 20%, 40%, 60%, 80%, and 100% was mixed and incubated at 55°C for half an hour to obtain a liposome drug preparation with a surface modified with a transmembrane peptide in a ratio of 0%, 1%, 2%, 3%, 4%, and 5%, namely 89W-CLS / R8 / FAM-siRNA.
[0172] Example 6. Quantitative evaluation of cell uptake of drug preparations with different ratios of cell-penetrating peptides on their surfaces
[0173] U87 cells (human glioma cells, purchased from ATCC) were cultured in DMEM complete medium (supplemented with 10% FBS and 1% penicillin-streptomycin). U87 cells with good growth status were resuspended in DMEM complete medium and cultured at 5×10 5 Cells / well were inoculated into 6-well plates, 1 mL per well. Fresh culture medium was replaced once a day after inoculation, and experiments were performed after 2 to 3 days of culture.
[0174] After discarding the culture medium, wash the U87 cells three times with sterile PBS, add 1 mL of serum-free DMEM medium containing liposome drug preparations (encapsulating FAM-labeled siRNA) with different ratios of surface-modified cell-penetrating peptides prepared in Example 5, and incubate for 4 h at 37°C and 5% CO2. After the incubation, discard the culture medium, and wash away the positively charged substances adsorbed on the pores or on the cell surface with a PBS buffer solution containing 0.02 mg / mL sodium heparin. Digest the cells with pancreatic enzymes, resuspend them in 200 μL of sterile PBS buffer solution, blow evenly, count the cells for each sample, and take 10 4 Cells were tested by flow cytometry. Cells incubated with serum-free DMEM medium were used as negative control group. All experiments were performed in triplicate. Fig.16 As shown (mean ± SD, n = 3, *p < 0.05, * indicates a statistically significant difference between the two groups; **p < 0.01, ***p < 0.001, ** and *** indicate very statistically significant differences between the two groups). Fig.16 "0%, 1%, 2%, 3%, 4%, 5%" on the horizontal axis respectively represent liposome drug preparations with surface modification of 0%, 1%, 2%, 3%, 4%, 5% of the membrane-penetrating peptide, i.e., 89W-CLS / R8 / siRNA.
[0175] Depend on Fig.16 visible, 89W Penetratin-PEG 3400 When the molar number of -DSPE accounts for 2%, 3%, and 4% of the total molar number of the liposome membrane material modified with the cell-penetrating peptide, the cell uptake effect of the drug preparation with the surface modified with the cell-penetrating peptide in the said proportion is better than the commercially available gene transfection reagent Lipo2000.
[0176] Example 7. Quantitative evaluation of cellular uptake of drug preparations prepared using liposome membrane materials modified with cell-penetrating peptides in different ratios
[0177] U87 cells (human glioma cells, purchased from ATCC) were cultured in DMEM complete medium (supplemented with 10% FBS and 1% penicillin-streptomycin). U87 cells with good growth status were resuspended in DMEM complete medium and cultured at 5×10 5 Cells / well were inoculated into 6-well plates, 1 mL per well. Fresh culture medium was replaced once a day after inoculation, and experiments were performed after 2 to 3 days of culture.
[0178] According to the method described in Example 5, a pharmaceutical preparation (encapsulating FAM-labeled siRNA) with a membrane material composition of a cell-penetrating peptide-modified liposome as shown in Table 2 was prepared.
[0179] Table 2. Different ratios of liposome membrane materials modified with cell-penetrating peptides (expressed in molar fraction, %)
[0180]
[0181] After discarding the culture medium of the cultured U87 cells, wash them three times with sterile PBS. Add 1 ml of serum-free DMEM medium containing the liposome drug preparations prepared by Formula 1, Formula 2, and Formula 3 to each well, and incubate for 4 hours at 37°C and 5% CO2. After the incubation, discard the culture medium and wash away the positively charged substances adsorbed on the wells or on the cell surface with a PBS buffer solution containing 0.02 mg / mL sodium heparin. Digest the cells with trypsin, resuspend them in 200 μL of sterile PBS buffer solution, blow evenly, count the cells for each sample, and take 10 4 Cells were tested by flow cytometry. Cells incubated with serum-free DMEM medium were used as negative control group. All experiments were performed in triplicate. Fig.17 As shown (mean ± SD, n = 3, *p < 0.05, * indicates a statistically significant difference between the two groups; **p < 0.01, ***p < 0.001, ** and *** indicate very statistically significant differences between the two groups).
[0182] Depend on Fig.17 It can be seen that the liposome drug preparations prepared using Formula 1, Formula 2, and Formula 3 can all be taken up by cells, with significant differences compared with the control group, and the cell uptake effect of the liposome drug preparation prepared using Formula 2 is the best.
[0183] Example 8. Particle size of drug preparations prepared using liposome membrane materials modified with cell-penetrating peptides in different ratios of component (iv)
[0184] According to the method described in Example 5, when the molar ratio of component (i): component (ii): component (iii) of the cell-penetrating peptide-modified liposome membrane material is 3:3:4, a liposome pharmaceutical preparation (encapsulating FAM-labeled siRNA) having a formulation of component (iv) as shown in Table 3 was prepared.
[0185] Table 3. Different ratios of component (iv) (expressed in mole fraction, %)
[0186]
[0187] The liposome drug preparations were obtained in which the component (iv) accounted for 1%, 5%, 8%, and 10% by mole of the liposome membrane material modified with the cell-penetrating peptide. The particle size of the liposome drug preparation was measured. The particle size measurement results are as follows: Fig.18 shown. Fig.18"1%, 5%, 8%, 10%" on the abscissa represent pharmaceutical preparations in which component (iv) accounts for 1%, 5%, 8%, 10% by mole of the liposome membrane material modified with the cell-penetrating peptide, respectively.
[0188] Depend on Fig.18 It can be seen that when component (iv) accounts for 1%-10% by mole of the liposome membrane material modified with the cell-penetrating peptide, the particle size of the drug preparation is between 100nm and 200nm; and as the mole fraction of component (iv) in the cell-penetrating peptide-modified liposome membrane material increases, the particle size tends to increase.
[0189] Example 9. Quantitative evaluation of cellular uptake of drug formulations prepared using different charge ratios of cationic liposomes / siRNA
[0190] U87 cells (human glioma cells, purchased from ATCC) were cultured in DMEM complete medium (supplemented with 10% FBS and 1% penicillin-streptomycin). U87 cells with good growth status were resuspended in DMEM complete medium and cultured at 5×10 5 Cells / well were inoculated into 6-well plates, 1 mL per well. Fresh culture medium was replaced once a day after inoculation, and experiments were performed after 2 to 3 days of culture.
[0191] According to the method described in Example 5, the oligoarginine R8 solution and the 20 μM FAM-siRNA solution were mixed in equal volumes at a charge ratio of 5, vortexed for 30 seconds, and incubated at 37° C. for 30 minutes to obtain the complex R8 / FAM-siRNA. 8 μL of the R8 / FAM-siRNA complex was taken and mixed with the prepared cationic liposome CLS at a charge ratio of liposome to FAM-siRNA of 2, 4, 6, 8, 10, and 12, and vortexed for 30 seconds to obtain CLS / R8 / FAM-siRNA complexes with different charge ratios of cationic liposome / siRNA.
[0192] Furthermore, according to the method described in Example 5, a liposome pharmaceutical preparation with 3% of the cell-penetrating peptide modified on the surface was obtained, namely, 89W-CLS / R8 / FAM-siRNA complex.
[0193] After discarding the culture medium of the cultured U87 cells, wash them three times with sterile PBS. Add 1 ml of serum-free DMEM medium containing cationic liposome / siRNA drug preparations with charge ratios of 2, 4, 6, 8, 10, and 12 to each well, and incubate for 4 hours at 37°C and 5% CO2. After the incubation, discard the culture medium and wash away the positively charged substances adsorbed on the wells or on the cell surface with PBS buffer solution containing 0.02 mg / mL sodium heparin. Digest the cells with trypsin, resuspend them in 200 μL sterile PBS buffer solution, blow evenly, count the cells for each sample, and take 104 Cells were tested by flow cytometry. Cells incubated with serum-free DMEM medium were used as negative control group. All experiments were performed in triplicate. Fig.19 As shown (mean ± SD, n = 3, *p < 0.05, * indicates a statistically significant difference between the two groups; **p < 0.01, ***p < 0.001, ** and *** indicate very statistically significant differences between the two groups).
[0194] Depend on Fig.19 It can be seen that the drug preparations prepared using cationic liposome / siRNA charge ratios of 2, 4, 6, 8, 10, and 12 can all be taken up by cells, with significant differences compared with the control group, and the cell uptake effect of the liposome drug preparation prepared using a cationic liposome / siRNA charge ratio of 4 is the best.
[0195] Example 10. Qualitative and quantitative evaluation of the transfection effect of pharmaceutical preparations containing cationic materials of different structural types on LUC-U87 cells
[0196] Oligoarginines such as R8, R10, R12, c-R8, c-R10 and c-R12 were selected as positively charged polyamino acids of different structural types, and the charge ratios of the oligoarginines to siRNA were 5, and the charge ratios of CLS to LUC-siRNA were 4. According to Example 5, liposome pharmaceutical preparations containing different oligoarginines and surface modified with 3% transmembrane peptides were prepared, wherein the sense chain (5'-3') of the LUC-siRNA used was GCUGCACUCUGGCGACAUUTT (SEQ ID NO: 83); the antisense chain (5'-3') was AAUGUCGCCAGAGUGCAGCTT (SEQ ID NO: 84).
[0197] U87 cells (purchased from ATCC) with good growth status were taken and cultured at 5×10 4Cells / well were inoculated into 48-well plates, and the medium was changed once a day after inoculation. The experiment was carried out after culturing for 2 to 3 days. After discarding the DMEM complete medium, the cells were washed three times with sterile PBS, and serum-free DMEM medium containing liposome drug preparations encapsulating 400nM LUC-siRNA was added respectively. The cells were incubated for 4 hours at 37°C and 5% CO2. The drug solution was then discarded, and DMEM complete medium was added to continue incubation for 24 hours (also referred to as LUC-U87 cells in the text). The positively charged adsorbed substances were washed away with PBS buffer solution containing 0.02mg / mL sodium heparin, and firefly luciferase substrate was added. The fluorescence intensity was measured in the small animal in vivo fluorescence / bioluminescence imaging system (IVIS Spectrum). Qualitative analysis was performed using the region of interest (ROI) quantitative selection function of the small animal in vivo optical imaging system. Results are shown in Fig. 20 shown.
[0198] This example is to explore the gene silencing effect of different structural types of positively charged polyamino acids. Fig. 20 It can be found that changing the polymerization degree and structure of oligoarginine in liposome drug preparations has no significant effect on gene silencing.
[0199] Example 11. Evaluation of the apoptosis-promoting ability of siRNA-encapsulated delivery vectors on bEnd.3 cells and U87 cells:
[0200] bEnd.3 cells and U87 cells (both purchased from ATCC) in good logarithmic growth state in DMEM medium were cultured at 5×10 4 The cells were plated at a concentration of 1 / well in 12-well plates and cultured at 37°C and 5% CO2 until the cell monolayer covered the bottom of the plate.
[0201] The culture medium was discarded, and the cells were washed three times with sterile PBS buffer. Then, 400 μL of the drug preparation prepared in Example 5 (89W-CLS / R8 / siRNA) containing 400 nmol / L siRNA was added. That is, the charge ratio of oligo-arginine to siRNA was 5, the charge ratio of CLS to siRNA was 4, and the surface modification ratio was 3%. 89W Penetratin-PEG 3400-DSPE drug preparation, incubated in a cell culture incubator for 6 hours, discarded the drug solution, washed 3 times with sterile PBS buffer, added 1mL of complete medium and continued to culture for 18 hours, then collected the cells, washed with PBS first, digested with EDTA-free trypsin for 1 minute, and collected the cells into a centrifuge tube after terminating the digestion with DMEM culture medium, double-stained the cells according to the steps of the cell apoptosis detection kit (Nanjing KeyGen Biotechnology Development Co., Ltd., KGA108), and then detected with a flow cytometer. Cells incubated with serum-free DMEM medium were used as the negative control group. All experiments were performed in triplicate, and the results are shown in Fig.21 As shown in panels A and B (mean ± SD, n = 3, *p < 0.05, * indicates a statistically significant difference between the two groups; **p < 0.01, ***p < 0.001, ** and *** indicate a very statistically significant difference between the two groups).
[0202] The results show that the delivery vector designed by the present invention can specifically promote the apoptosis of tumor cells U87, but has no significant effect on the growth of normal cells bEnd.3 cells.
[0203] Example 12. Half inhibitory concentration IC of each chemotherapeutic drug and gene drug 50 Value determination:
[0204] IC50 inhibitory concentration of chemotherapeutic drugs 50 The determination of the value requires the preparation of a density of 3×10 4 The cells were inoculated with a single cell suspension of U87 cells / mL in a 96-well plate with a volume of 100 μL per well. The edge wells were filled with sterile PBS buffer solution and moved into a CO2 incubator (37°C, 5% CO2, saturated humidity) for 24 h. The original culture medium was discarded and replaced with 200 μL of culture medium containing chemotherapeutic drugs, namely carmustine (BCNU, Dalian Meilun Biotechnology Co., Ltd., MB130), docetaxel (DTX, Dalian Meilun Biotechnology Co., Ltd., MB1081), gemcitabine (Gemcitabine, Dalian Meilun Biotechnology Co., Ltd., MB5386), imatinib (Imatinib, Dalian Meilun Biotechnology Co., Ltd., MB2031), cisplatin (Cisplatin, Dalian Meilun Biotechnology Co., Ltd., MB1055) and doxorubicin (DOX, Dalian Meilun Biotechnology Co., Ltd., MB1087), or culture medium without chemotherapeutic drugs for cell culture. After 48 h, 10 μL of cck-8 solution (Shanghai Biotech Co., Ltd., C0042) was added to each well, and the cells were incubated at 37°C for 2 h before measuring the OD value of each well at a wavelength of 490 nm using a microplate reader (BioTek, PowerWave XS).
[0205] IC50 inhibitory concentration of gene drugs50 The determination of the value requires the preparation of a density of 1×10 5 The suspension of U87 cells / mL was inoculated into a 24-well plate with a volume of 500 μL per well, and then placed in a CO2 incubator (37°C, 5% CO2, saturated humidity) for 24 h. The original culture medium was discarded, and 400 μL of the liposome preparation (89WP-CLS / R8 / siRNA) prepared in Example 5 containing siRNA was added, wherein the charge ratio of oligoarginine to siRNA was 5, the charge ratio of CLS to siRNA was 4, and the surface modification had a ratio of 3% 89W Penetratin-PEG 3400 -DSPE liposome drug preparation, discard the drug solution after 6 hours, digest the cells again, inoculate in a 96-well plate at a concentration of 3000 cells / well, add fresh DMEM complete medium (10% FBS and 1% penicillin-streptomycin) and continue to culture. After 48 hours, add 10 μL cck-8 solution to each well, continue incubation at 37°C for 2 hours, and measure the OD value of each well at a wavelength of 490nm on an ELISA reader.
[0206] Cell survival rate (%) = (OD s -OD blank ) / (OD control -OD blank )×100%. In the formula, OD s is the absorbance of the drug-treated group, OD control is the absorbance of the blank control group (only cells, DMEM complete medium and cck-8 were added to the wells), OD blank = is the absorbance of the blank well (only DMEM complete medium and cck-8 were added to the well). All experiments were performed in triplicate, and the experimental results were analyzed using Graphpad Prism software. Fig. 22 shown.
[0207] The results showed that the half inhibitory concentrations IC of chemotherapeutic drugs BCNU, DTX, Gemcitabine, Imatinib, Cisplatin and DOX 50 The values are 92.04μM, 15.52nM, 0.11μM, 41.59μM, 5.62μM and 0.17μM respectively. The half inhibitory concentration IC of gene drug siRNA 50 The value is 90.99nM.
[0208] Example 13. In vitro evaluation of anti-tumor efficacy of gene drugs combined with different chemotherapeutic drugs:
[0209] The preparation density is 1×10 5The suspension of U87 cells / mL was inoculated into a 24-well plate with a volume of 500 μL per well, and then transferred into a CO2 incubator (37°C, 5% CO2, saturated humidity) for 24 h. The original culture medium was discarded, and 400 μL of the liposome preparation prepared in Example 5 (89WP-CLS / R8 / siRNA) containing siRNA was added, i.e., the charge ratio of oligoarginine to siRNA was 5, the charge ratio of CLS to siRNA was 4, and the surface modification had a ratio of 3% 89W Penetratin-PEG 3400 -DSPE liposome drug preparation, the drug solution was discarded after 6 hours, the cells were digested again, and seeded in a 96-well plate at a concentration of 3000 cells / well, and fresh DMEM complete medium (supplemented with 10% FBS and 1% penicillin-streptomycin) was added to continue culturing for 12 hours, and then the medium was replaced with complete medium containing different chemotherapeutic drugs (BCNU, DTX, Gemcitabine, Imatinib, Cisplatin and DOX) and continued to be cultured (the molar concentration ratio of gene drugs and chemotherapeutic drugs was the half inhibitory concentration IC of both) 50 After 48 h, 10 μL of CCK-8 solution was added to each well, and the cells were incubated at 37°C for 2 h. The OD value of each well was measured at 490 nm using an ELISA reader.
[0210] Cell survival rate (%) = (OD s -OD blank ) / (OD control -OD blank )×100%. In the formula, OD s is the absorbance of the drug-treated group, OD control is the absorbance of the blank control group (only cells, DMEM complete medium and cck-8 were added to the wells), OD blank = is the absorbance of the blank well (only DMEM complete medium and cck-8 were added to the well). All experiments were performed in triplicate. Fig.23 shown.
[0211] The experimental results were further analyzed using CompuSyn software to obtain the combination index and dose reduction index of the combination of gene drugs and different chemotherapy drugs. The calculation results are as follows Fig.24 shown.
[0212] Depend on Fig.24It can be seen that different chemotherapy drugs BCNU, DTX, Gemcitabine, Imatinib, Cisplatin and DOX respectively cooperate with gene drug siRNA to reduce cell survival rate. In particular, the combination index of chemotherapy drugs DTX, Gemcitabine, Cisplatin and DOX with gene drugs is less than 1, and the dose reduction index is greater than 1, indicating that there is a better combined treatment effect of synergistic effect. However, the combination index of chemotherapy drugs BCNU and Imatinib with gene drugs is greater than 1, and the dose reduction index is less than 1, indicating that although there is a synergistic effect, the dose reduction used in combined treatment is not as good as that of chemotherapy drugs DTX, Gemcitabine, Cisplatin and DOX. Therefore, chemotherapy drugs DTX, Gemcitabine, Cisplatin and DOX are included in the scope of further experiments to screen out the best chemotherapy drugs used in combination with gene drugs at a specific total dosage.
[0213] Example 14. In vitro anti-tumor pharmacodynamic screening of gene drugs combined with different chemotherapeutic drugs:
[0214] The preparation density is 1×10 5 The suspension of U87 cells / mL was inoculated into a 24-well plate with a volume of 500 μL per well, and then transferred into a CO2 incubator (37°C, 5% CO2, saturated humidity) for 24 h. The original culture medium was discarded, and 400 μL of the liposome preparation prepared in Example 5 (89WP-CLS / R8 / siRNA) containing siRNA was added, i.e., the charge ratio of oligoarginine to siRNA was 5, the charge ratio of CLS to siRNA was 4, and the surface modification had a ratio of 3% 89W Penetratin-PEG 3400 -DSPE liposome drug preparation, discard the drug solution after 6 hours, digest the cells again, inoculate at a concentration of 3000 cells / well in a 96-well plate, add fresh DMEM complete medium (supplemented with 10% FBS and 1% penicillin-streptomycin) and continue to culture for 12 hours, then replace the medium with DMEM complete medium containing different chemotherapeutic drugs (DTX, Gemcitabine, Cisplatin and DOX) and continue to culture (the concentration ratio of gene drug and chemotherapeutic drug is the half inhibitory concentration IC of both) 50 After 48 h, 10 μL of cck-8 solution was added to each well, and the cells were incubated at 37°C for 2 h before the OD value of each well was measured at a wavelength of 490 nm on a microplate reader.
[0215] Cell survival rate (%) = (OD s -OD blank ) / (OD control-OD blank )×100%. In the formula, OD s is the absorbance of the drug-treated group, OD control is the absorbance of the blank control group (only cells, DMEM complete medium and cck-8 were added to the wells), OD blank = is the absorbance of the blank well (only DMEM complete medium and cck-8 were added to the well). All experiments were performed in triplicate, and the experimental results were analyzed using Graphpad Prism software. Fig.25 As shown (mean ± SD, n = 3, *p < 0.05, * indicates that there is a statistically significant difference between the two groups; ***p < 0.001, *** indicates that there is a very significant statistical difference between the two groups; ns indicates that there is no statistically significant difference between the two groups).
[0216] The results showed that when the concentration ratio of gene drug and chemotherapy drug was the half inhibitory concentration IC 50 The ratio of the values of gene drugs and chemotherapy drugs was 200nM. When the sum of the concentrations of gene drugs and chemotherapy drugs was 200nM, the combination of gene drugs and chemotherapy drugs DTX had the greatest inhibitory effect on cell survival, indicating that it had the best in vitro anti-tumor effect. Based on this result, at a specific total dosage, the gene drug was combined with the chemotherapy drug DTX for later experimental research.
[0217] Example 15. Preparation of cationic liposomes and positively charged polyamino acids encapsulating gene drugs and chemotherapeutic drugs:
[0218] Similarly as described in Example 1, the membrane materials, namely 3.5 mg of DOTAP, 3.72 mg of DOPE, and 2.59 mg of cholesterol, were weighed, 4 μg of DTX API (Dalian Meilun Biotechnology Co., Ltd., MB1081) was added, and dissolved in chloroform. The resulting solution was removed by a rotary evaporator (Shanghai Shensheng Technology Co., Ltd., R201L) to remove chloroform, and the resulting dried lipid film was hydrated with 1 mL of 5% glucose aqueous solution by ultrasonic hydration in a 37°C water bath for about 10 minutes. After the lipid film was completely hydrated, it was extruded using a micro extruder (Hamilton, 81320) (the order of passing through the nuclear pore membrane was 200 nm, 100 nm, and 50 nm), and CLS (CLS / DTX) loaded with DTX was obtained.
[0219] Similarly as described in Example 4, the prepared R8 / siRNA complex and CLS / DTX were used to prepare liposome complexes CLS / DTX / R8 / siRNA.
[0220] Similar to Example 5, the prepared CLS / DTX / R8 / siRNA complexes were respectively 89WPenetratin-PEG 3400 -The molar number of DSPE in mPEG 2000 -DSPE and 89W Penetratin-PEG 3400 -DSPE was mixed and incubated at 55°C for half an hour to obtain a liposome drug preparation with a surface modification of 3% of the cell-penetrating peptide, i.e., 89WP-CLS / DTX / R8 / siRNA, wherein the molar concentration ratio of the gene drug siRNA and the chemotherapy drug DTX was IC 50 The molar concentration of the gene drug siRNA is about 6, and the molar concentration of the chemotherapeutic drug DTX is 1.03 μM.
[0221] Example 16. In vitro anti-tumor pharmacodynamics evaluation of gene drugs combined with chemotherapy drug docetaxel (DTX):
[0222] The preparation density is 5×10 4 The suspension of U87 cells / mL was inoculated into a 24-well plate with a volume of 500 μL per well, and the plate was placed in a CO2 incubator (37°C, 5% CO2, saturated humidity) for 24 h. The original culture medium was discarded, and 400 μL of the liposome preparation 89WP-CLS / DTX / R8 / siRNA or CLS / DTX / R8 / siRNA prepared in Example 15 containing siRNA was added, or 400 μL of 89WP-CLS / R8 / siRNA+DTX was added, i.e., the charge ratio of oligoarginine to siRNA was 5, the charge ratio of CLS to siRNA was 4, and the surface modification had a ratio of 3% 89W Penetratin-PEG 3400 -DSPE liposome drug preparation. The preparation of 89WP-CLS / R8 / siRNA+DTX is obtained by physically mixing 89WP-CLS / R8 / siRNA and DTX. The molar concentration ratio of the gene drug siRNA and the chemotherapy drug DTX is both IC 50 After 6 hours, the drug solution was discarded, the cells were digested again, and inoculated in a 96-well plate at a concentration of 3000 cells / well. Fresh DMEM complete medium (with 10% FBS and 1% penicillin-streptomycin) was added to continue culturing. After 48 hours, 10 μL of cck-8 solution was added to each well, and the OD value of each well was measured at a wavelength of 490 nm on an ELISA reader after incubation at 37°C for 2 hours.
[0223] Cell survival rate (%) = (ODs-ODblank) / (ODcontrol-ODblank) × 100%. In the formula, ODs is the absorbance of the drug-treated group, ODcontrol is the absorbance of the blank control group (only cells, DMEM complete medium and cck-8 were added to the wells), and ODblank is the absorbance of the blank wells (only DMEM complete medium and cck-8 were added to the wells). All experiments were performed in triplicate, and the experimental results were analyzed using Graphpad Prism software. The results are shown in Fig.26 (mean ± SD, n = 3, ns means there is no statistically significant difference between the two groups).
[0224] The results are as follows Fig.26 As shown, the half inhibitory concentration IC of DTX in the liposome formulation 89WP-CLS / DTX / R8 / siRNA 50 The value is 8.9 nM; the half inhibitory concentration IC of DTX in the liposome formulation CLS / DTX / R8 / siRNA 50 The value is 24.7nM; the half inhibitory concentration IC of DTX when the liposome formulation 89WP-CLS / R8 / siRNA is combined with DTX 50 The value is 10.3 nM. It can be seen that when DTX acts for only 6 hours, the combination of siRNA and DTX in the liposome preparation of the present invention can significantly reduce the half inhibitory concentration of DTX and has a more efficient tumor inhibition effect.
[0225] Example 17. Investigating the uptake of FAM-siRNA by cells after the carrier labeled with DiD cell membrane fluorescent probe was loaded:
[0226] Similar to Example 1, the membrane material was weighed, and DiD cell membrane fluorescent probe (Dalian Meilun Biotechnology Co., Ltd., MB6190) was added according to the instructions of the kit to prepare CLS labeled with DiD cell membrane fluorescent probe, i.e., CLS / DiD. 33 μg of FAM-labeled siRNA (in this example, siRNA targeting c-myc was used, and its sense strand (5'-3') was FAM-AACGUUAGCUUCACCAACAdTdT, i.e., 5' was modified with FAM; the antisense strand (5'-3') was UGUUGGUGAAGCUAACGUUdTdT) was dissolved in 125 μL of DEPC-treated water to prepare a 20 μM FAM-siRNA solution, and each drug preparation labeled with DiD and / or FAM fluorescence was prepared.
[0227] U87 cells (human glioma cells, purchased from ATCC) or Calu-3 cells (human lung adenocarcinoma cells, purchased from ATCC) were cultured in DMEM complete medium (supplemented with 10% FBS and 1% penicillin-streptomycin). U87 cells or Calu-3 cells with good growth status were resuspended in DMEM complete medium and cultured at 5×10 5 Cells / well were inoculated into 6-well plates, 1 mL per well. Fresh culture medium was replaced once a day after inoculation, and experiments were performed after 2 to 3 days of culture.
[0228] After discarding the culture medium of the cultured U87 cells or Calu-3 cells, wash them three times with sterile PBS. Add 1 mL of serum-free DMEM medium containing 1 μM siRNA and different fluorescently labeled drug preparations to each well and incubate for 4 hours at 37°C and 5% CO2. After the incubation, discard the culture medium and wash away the positively charged substances adsorbed on the wells or on the cell surface with PBS buffer solution containing 0.02 mg / mL sodium heparin. Digest the cells with trypsin, resuspend them in 200 μL sterile PBS buffer solution, blow evenly, count the cells for each sample, and take 10 4 Cells were subjected to flow cytometry detection. In the experiment, cells incubated with blank serum-free DMEM medium were set up as a negative control group; in addition, two positive control groups were set up, namely 89WP-CLS / R8 / FAM-siRNA containing only FAM, and 89WP-CLS / DiD containing only DiD; the following preparation groups were also set up: 89WP-CLS / DiD / R8 / siRNA group, CLS / DiD / R8 / FAM-siRNA group, 89WP-CLS / DiD / R8 / FAM-siRNA group. All experiments were performed in triplicate. The dosage volume of all preparations was 1 mL, of which the concentration of siRNA was about 1 μM, and the concentration of DTX was about 0.1667 μM (the molar concentration ratio of DTX and siRNA was IC 50 The ratio of the charge of oligo-arginine to siRNA is 5, the charge of CLS to siRNA is 4, and the surface modification has a ratio of 3%. 89W Penetratin-PEG 3400 -DSPE. The results are as follows Fig. 27 As shown (mean ± SD, n = 3, ***p < 0.001, *** indicates a very significant difference between the two groups in statistics).
[0229] Depend on Fig. 27As can be seen from the results, the uptake of the 89WP-CLS / DiD / R8 / FAM-siRNA drug preparation in U87 cells and Calu-3 cells showed stronger DiD and FAM double fluorescence positive results. Therefore, the fluorescent probe DiD embedded in the liposome membrane and the siRNA encapsulated in the liposome were co-incorporated into the cell in the form of a lipid complex, and were not taken up in a free form. Since the chemotherapeutic drug DTX and the fluorescent probe DiD have similar physical and chemical properties, it is speculated that when the drug preparation 89WP-CLS / DTX / R8 / siRNA that co-encapsulates the gene drug and the chemotherapeutic drug is taken up by the cell, the gene drug siRNA and the chemotherapeutic drug DTX are also taken up together in the form of a lipid complex and enter the cell.
[0230] Example 18. Evaluation of the ability of gene drugs combined with DTX chemotherapy drugs to promote apoptosis of U87 cells:
[0231] U87 cells (purchased from ATCC) in good logarithmic growth state in DMEM medium were cultured at 5×10 4 The cells were plated at a concentration of 1 / well in 12-well plates and cultured at 37°C and 5% CO2 until the cell monolayer covered the bottom of the plate.
[0232] The culture medium was discarded, and the cells were washed three times with sterile PBS buffer. Then, 400 μL of the liposome preparation 89WP-CLS / DTX / R8 / siRNA prepared in Example 15, CLS / DTX / R8 / siRNA, the liposome preparation 89WP-CLS / R8 / siRNA prepared in Example 5, and a physical mixture of 89WP-CLS / R8 / siRNA and DTX containing 150 nmol / L siRNA were added, respectively. That is, the administration volume of each preparation was 400 μL, wherein the concentration of siRNA was diluted to 150 nmol / L, the charge ratio of oligoarginine to siRNA was 5, the charge ratio of CLS to siRNA was 4, and the surface modification had a ratio of 3%. 89W Penetratin-PEG 3400 -The molar concentration ratio of DSPE, DTX and siRNA is IC 50 The ratio of the value is 6. After incubation in the cell culture incubator for 6 hours, the drug solution was discarded, and the cells were washed 3 times with sterile PBS buffer. 1 mL of complete medium was added and cultured for 18 hours. After that, the cells were collected, washed with PBS, digested with EDTA-free trypsin for 1 minute, and then the cells were collected into a centrifuge tube after terminating the digestion with DMEM culture medium. The cells were double-stained according to the steps of the cell apoptosis detection kit (Nanjing KeyGen Biotechnology Development Co., Ltd., KGA108), and then detected by flow cytometer. Cells incubated with serum-free DMEM medium were used as the negative control group. All experiments were performed in triplicate, and the results are shown in Fig.28As shown (mean ± SD, n = 3, **p < 0.01, ***p < 0.001, ** and *** indicate that there are very significant statistical differences between the two groups).
[0233] The results show that the drug preparation designed by the present invention for co-delivering gene drugs and chemotherapy drugs can significantly increase the apoptosis rate of tumor cells U87 and has a more efficient tumor inhibition effect.
[0234] Example 19. Pharmacodynamic evaluation of gene therapy combined with DTX chemotherapy against U87 brain tumor in situ:
[0235] U87 cells in the logarithmic growth phase were collected, counted, and resuspended in PBS buffer. Each BALB / c nude mouse (Shanghai Xipu-Bikai Experimental Animal Co., Ltd., China) was inoculated with 6×10 5 U87 cells (dispersed in 5 μL PBS buffer) were added. Nude mice were anesthetized with 7% chloral hydrate, fixed in a stereotaxic apparatus, and the cells were inoculated into the striatum (0.6 mm forward, 1.8 mm to the right, and 3 mm deep) using a microinjector to construct a U87 orthotopic brain tumor model.
[0236] According to the method described in the previous examples, liposome drug preparations, namely CLS / DTX / R8 / siRNA, 89WP-CLS / R8 / siRNA, 89WP-CLS / DTX / R8 / siRNA, and a physical mixture of 89WP-CLS / R8 / siRNA+DTX were prepared respectively.
[0237] After inoculation of U87 brain orthotopic tumor, mice were randomly divided into 6 groups (n=10): normal saline group, DTX group, CLS / DTX / R8 / siRNA group, 89WP-CLS / R8 / siRNA group, 89WP-CLS / DTX / R8 / siRNA group, and 89WP-CLS / R8 / siRNA+DTX group. Nasal administration was started on the 5th day after inoculation of U87 tumor cells, with a dose of 0.66 mg / kg siRNA (CLS / DTX / R8 / siRNA group, 89WP-CLS / R8 / siRNA group, 89WP-CLS / DTX / R8 / siRNA group, 89WP-CLS / R8 / siRNA+DTX group), 6.66 μg / kg DTX (DTX group, CLS / DTX / R8 / siRNA group, 89WP-CLS / DTX / R8 / siRNA group, 89WP-CLS / R8 / siRNA+DTX group). In all the administration preparations, the charge ratio of oligoarginine to siRNA was 5, the charge ratio of CLS to siRNA was 4, and the surface modification was 3% 89WPenetratin-PEG. 3400-The molar concentration ratio of DSPE, DTX and siRNA is IC 50 The ratio of the values is 6. The drug was administered once a day for a total of 22 times. The weight and survival period of the mice were recorded, and the weight change curve and survival curve were drawn. The results are shown in Fig.29 , Fig.30 As shown (**p<0.01, ***p<0.001, ** and *** indicate that there are very significant statistical differences between the two groups).
[0238] The results showed that the median survival times of the saline group, DTX group, CLS / DTX / R8 / siRNA group, 89WP-CLS / R8 / siRNA group, and 89WP-CLS / R8 / siRNA+DTX group were 20 days, 21 days, 27 days, 27 days, and 28.5 days, respectively. The 89WP-CLS / DTX / R8 / siRNA group successfully extended the median survival time to 33.5 days, and the survival curve did not intersect with those of other groups, achieving the most significant anti-glioma effect. These data confirmed that 89WP-CLS / DTX / R8 / siRNA can deliver drugs to brain tumors and exert anti-tumor effects, and its unique delivery advantages can be converted into higher therapeutic efficacy.
[0239] Although certain representative embodiments and details have been shown for the purpose of illustrating the present invention, it will be apparent to those skilled in the art that various changes and modifications may be made thereto without departing from the scope of the subject invention. In this regard, the scope of the present invention is limited only by the following claims. Sequence Listing <110> Fudan University JSR Co., Ltd. <120> Drug delivery carrier and drug preparation for co-delivering multiple therapeutic agents using the same <130> <160> 88 <170> PatentIn Version 3.3 <210> 1 <211> 16 <212> PRT <213> Artificial sequence <220> <221> misc_feature <222> (2) <223> Xaa can be any of Gln, Asn, Ala, Val, Leu, Ile, Pro, Phe, Trp, Met, α-aminobutyric acid, α-aminovaleric acid, α-aminocaproic acid, α-aminoheptanoic acid <220> <221> misc_feature <222> (8)..(9) <223> Xaa can be any of Gln, Asn, Ala, Val, Leu, Ile, Pro, Phe, Trp, Met, α-aminobutyric acid, α-aminovaleric acid, α-aminocaproic acid, α-aminoheptanoic acid <400> 1 Arg Xaa Ile Lys Ile Trp Phe Xaa Xaa Arg Arg Met Lys Trp Lys Lys 1 5 10 15 <210> 2 <211> 16 <212> PRT <213> Artificial sequence <400> 2 Arg Gln Ile Lys Ile Trp Phe Gln Asn Arg Arg Met Lys Trp Lys Lys 1 5 10 15 <210> 3 <211> 16 <212> PRT <213> Artificial sequence <400> 3 Arg Ala Ile Lys Ile Trp Phe Gln Asn Arg Arg Met Lys Trp Lys Lys 1 5 10 15 <210> 4 <211> 16 <212> PRT <213> Artificial sequence <400> 4 Arg Gln Ile Lys Ile Trp Phe Ala Asn Arg Arg Met Lys Trp Lys Lys 1 5 10 15 <210> 5 <211> 16 <212> PRT <213> Artificial sequence <400> 5 Arg Gln Ile Lys Ile Trp Phe Gln Ala Arg Arg Met Lys Trp Lys Lys 1 5 10 15 <210> 6 <211> 16 <212> PRT <213> artificial sequence <400> 6 Arg Ala Ile Lys Ile Trp Phe Ala Asn Arg Arg Met Lys Trp Lys Lys 1 5 10 15 <210> 7 <211> 16 <212> PRT <213> artificial sequence <400> 7 Arg Ala Ile Lys Ile Trp Phe Gln Ala Arg Arg Met Lys Trp Lys Lys 1 5 10 15 <210> 8 <211> 16 <212> PRT <213> artificial sequence <400> 8 Arg Gln Ile Lys Ile Trp Phe Ala Ala Arg Arg Met Lys Trp Lys Lys 1 5 10 15 <210> 9 <211> 16 <212> PRT <213> artificial sequence <400> 9 Arg Ala Ile Lys Ile Trp Phe Ala Ala Arg Arg Met Lys Trp Lys Lys 1 5 10 15 <210> 10 <211> 16 <212> PRT <213> Artificial sequence <400> 10 Arg Leu Ile Lys Ile Trp Phe Gln Asn Arg Arg Met Lys Trp Lys Lys 1 5 10 15 <210> 11 <211> 16 <212> PRT <213> Artificial sequence <400> 11 Arg Gln Ile Lys Ile Trp Phe Leu Asn Arg Arg Met Lys Trp Lys Lys 1 5 10 15 <210> 12 <211> 16 <212> PRT <213> Artificial sequence <400> 12 Arg Gln Ile Lys Ile Trp Phe Gln Leu Arg Arg Met Lys Trp Lys Lys 1 5 10 15 <210> 13 <211> 16 <212> PRT <213> Artificial sequence <400> 13 Arg Leu Ile Lys Ile Trp Phe Leu Asn Arg Arg Met Lys Trp Lys Lys 1 5 10 15 <210> 14 <211> 16 <212> PRT <213> Artificial sequence <400> 14 Arg Leu Ile Lys Ile Trp Phe Gln Leu Arg Arg Met Lys Trp Lys Lys 1 5 10 15 <210> 15 <211> 16 <212> PRT <213> Artificial sequence <400> 15 Arg Gln Ile Lys Ile Trp Phe Leu Leu Arg Arg Met Lys Trp Lys Lys 1 5 10 15 <210> 16 <211> 16 <212> PRT <213> Artificial sequence <400> 16 Arg Leu Ile Lys Ile Trp Phe Leu Leu Arg Arg Met Lys Trp Lys Lys 1 5 10 15 <210> 17 <211> 16 <212> PRT <213> Artificial sequence <400> 17 Arg Pro Ile Lys Ile Trp Phe Gln Asn Arg Arg Met Lys Trp Lys Lys 1 5 10 15 <210> 18 <211> 16 <212> PRT <213> Artificial sequence <400> 18 Arg Gln Ile Lys Ile Trp Phe Pro Asn Arg Arg Met Lys Trp Lys Lys 1 5 10 15 <210> 19 <211> 16 <212> PRT <213> Artificial sequence <400> 19 Arg Gln Ile Lys Ile Trp Phe Gln Pro Arg Arg Met Lys Trp Lys Lys 1 5 10 15 <210> 20 <211> 16 <212> PRT <213> Artificial sequence <400> 20 Arg Pro Ile Lys Ile Trp Phe Pro Asn Arg Arg Met Lys Trp Lys Lys 1 5 10 15 <210> twenty one <211> 16 <212> PRT <213> Artificial sequence <400> twenty one Arg Pro Ile Lys Ile Trp Phe Gln Pro Arg Arg Met Lys Trp Lys Lys 1 5 10 15 <210> twenty two <211> 16 <212> PRT <213> Artificial sequence <400> twenty two Arg Gln Ile Lys Ile Trp Phe Pro Pro Arg Arg Met Lys Trp Lys Lys 1 5 10 15 <210> twenty three <211> 16 <212> PRT <213> Artificial sequence <400> twenty three Arg Pro Ile Lys Ile Trp Phe Pro Pro Arg Arg Met Lys Trp Lys Lys 1 5 10 15 <210> twenty four <211> 16 <212> PRT <213> Artificial sequence <400> twenty four Arg Trp Ile Lys Ile Trp Phe Gln Asn Arg Arg Met Lys Trp Lys Lys 1 5 10 15 <210> 25 <211> 16 <212> PRT <213> artificial sequence <400> 25 Arg Gln Ile Lys Ile Trp Phe Trp Asn Arg Arg Met Lys Trp Lys Lys 1 5 10 15 <210> 26 <211> 16 <212> PRT <213> artificial sequence <400> 26 Arg Gln Ile Lys Ile Trp Phe Gln Trp Arg Arg Met Lys Trp Lys Lys 1 5 10 15 <210> 27 <211> 16 <212> PRT <213> artificial sequence <400> 27 Arg Trp Ile Lys Ile Trp Phe Trp Asn Arg Arg Met Lys Trp Lys Lys 1 5 10 15 <210> 28 <211> 16 <212> PRT <213> artificial sequence <400> 28 Arg Trp Ile Lys Ile Trp Phe Gln Trp Arg Arg Met Lys Trp Lys Lys 1 5 10 15 <210> 29 <211> 16 <212> PRT <213> artificial sequence <400> 29 Arg Gln Ile Lys Ile Trp Phe Trp Trp Arg Arg Met Lys Trp Lys Lys 1 5 10 15 <210> 30 <211> 16 <212> PRT <213> artificial sequence <400> 30 Arg Trp Ile Lys Ile Trp Phe Trp Trp Arg Arg Met Lys Trp Lys Lys 1 5 10 15 <210> 31 <211> 16 <212> PRT <213> artificial sequence <400> 31 Arg Ala Ile Lys Ile Trp Phe Val Asn Arg Arg Met Lys Trp Lys Lys 1 5 10 15 <210> 32 <211> 16 <212> PRT <213> artificial sequence <400> 32 Arg Val Ile Lys Ile Trp Phe Ala Asn Arg Arg Met Lys Trp Lys Lys 1 5 10 15 <210> 33 <211> 16 <212> PRT <213> artificial sequence <400> 33 Arg Val Ile Lys Ile Trp Phe Gln Leu Arg Arg Met Lys Trp Lys Lys 1 5 10 15 <210> 34 <211> 16 <212> PRT <213> artificial sequence <400> 34 Arg Leu Ile Lys Ile Trp Phe Gln Val Arg Arg Met Lys Trp Lys Lys 1 5 10 15 <210> 35 <211> 16 <212> PRT <213> artificial sequence <400> 35 Arg Leu Ile Lys Ile Trp Phe Gln Ile Arg Arg Met Lys Trp Lys Lys 1 5 10 15 <210> 36 <211> 16 <212> PRT <213> artificial sequence <400> 36 Arg Ile Ile Lys Ile Trp Phe Gln Leu Arg Arg Met Lys Trp Lys Lys 1 5 10 15 <210> 37 <211> 16 <212> PRT <213> artificial sequence <400> 37 Arg Ile Ile Lys Ile Trp Phe Pro Asn Arg Arg Met Lys Trp Lys Lys 1 5 10 15 <210> 38 <211> 16 <212> PRT <213> artificial sequence <400> 38 Arg Pro Ile Lys Ile Trp Phe Ile Asn Arg Arg Met Lys Trp Lys Lys 1 5 10 15 <210> 39 <211> 16 <212> PRT <213> Artificial sequence <400> 39 Arg Pro Ile Lys Ile Trp Phe Phe Asn Arg Arg Met Lys Trp Lys Lys 1 5 10 15 <210> 40 <211> 16 <212> PRT <213> Artificial sequence <400> 40 Arg Phe Ile Lys Ile Trp Phe Pro Asn Arg Arg Met Lys Trp Lys Lys 1 5 10 15 <210> 41 <211> 16 <212> PRT <213> Artificial sequence <400> 41 Arg Val Ile Lys Ile Trp Phe Gln Asn Arg Arg Met Lys Trp Lys Lys 1 5 10 15 <210> 42 <211> 16 <212> PRT <213> Artificial sequence <400> 42 Arg Gln Ile Lys Ile Trp Phe Val Asn Arg Arg Met Lys Trp Lys Lys 1 5 10 15 <210> 43 <211> 16 <212> PRT <213> Artificial sequence <400> 43 Arg Gln Ile Lys Ile Trp Phe Gln Val Arg Arg Met Lys Trp Lys Lys 1 5 10 15 <210> 44 <211> 16 <212> PRT <213> Artificial sequence <400> 44 Arg Val Ile Lys Ile Trp Phe Val Asn Arg Arg Met Lys Trp Lys Lys 1 5 10 15 <210> 45 <211> 16 <212> PRT <213> Artificial sequence <400> 45 Arg Val Ile Lys Ile Trp Phe Gln Val Arg Arg Met Lys Trp Lys Lys 1 5 10 15 <210> 46 <211> 16 <212> PRT <213> Artificial sequence <400> 46 Arg Gln Ile Lys Ile Trp Phe Val Val Arg Arg Met Lys Trp Lys Lys 1 5 10 15 <210> 47 <211> 16 <212> PRT <213> Artificial sequence <400> 47 Arg Val Ile Lys Ile Trp Phe Val Val Arg Arg Met Lys Trp Lys Lys 1 5 10 15 <210> 48 <211> 16 <212> PRT <213> Artificial sequence <400> 48 Arg Ile Ile Lys Ile Trp Phe Gln Asn Arg Arg Met Lys Trp Lys Lys 1 5 10 15 <210> 49 <211> 16 <212> PRT <213> artificial sequence <400> 49 Arg Gln Ile Lys Ile Trp Phe Ile Asn Arg Arg Met Lys Trp Lys Lys 1 5 10 15 <210> 50 <211> 16 <212> PRT <213> artificial sequence <400> 50 Arg Gln Ile Lys Ile Trp Phe Gln Ile Arg Arg Met Lys Trp Lys Lys 1 5 10 15 <210> 51 <211> 16 <212> PRT <213> artificial sequence <400> 51 Arg Ile Ile Lys Ile Trp Phe Ile Asn Arg Arg Met Lys Trp Lys Lys 1 5 10 15 <210> 52 <211> 16 <212> PRT <213> artificial sequence <400> 52 Arg Ile Ile Lys Ile Trp Phe Gln Ile Arg Arg Met Lys Trp Lys Lys 1 5 10 15 <210> 53 <211> 16 <212> PRT <213> artificial sequence <400> 53 Arg Gln Ile Lys Ile Trp Phe Ile Ile Arg Arg Met Lys Trp Lys Lys 1 5 10 15 <210> 54 <211> 16 <212> PRT <213> artificial sequence <400> 54 Arg Ile Ile Lys Ile Trp Phe Ile Ile Arg Arg Met Lys Trp Lys Lys 1 5 10 15 <210> 55 <211> 16 <212> PRT <213> artificial sequence <400> 55 Arg Phe Ile Lys Ile Trp Phe Gln Asn Arg Arg Met Lys Trp Lys Lys 1 5 10 15 <210> 56 <211> 16 <212> PRT <213> artificial sequence <400> 56 Arg Gln Ile Lys Ile Trp Phe Phe Asn Arg Arg Met Lys Trp Lys Lys 1 5 10 15 <210> 57 <211> 16 <212> PRT <213> artificial sequence <400> 57 Arg Gln Ile Lys Ile Trp Phe Gln Phe Arg Arg Met Lys Trp Lys Lys 1 5 10 15 <210> 58 <211> 16 <212> PRT <213> Artificial sequence <400> 58 Arg Phe Ile Lys Ile Trp Phe Phe Asn Arg Arg Met Lys Trp Lys Lys 1 5 10 15 <210> 59 <211> 16 <212> PRT <213> Artificial sequence <400> 59 Arg Phe Ile Lys Ile Trp Phe Gln Phe Arg Arg Met Lys Trp Lys Lys 1 5 10 15 <210> 60 <211> 16 <212> PRT <213> Artificial sequence <400> 60 Arg Gln Ile Lys Ile Trp Phe Phe Phe Arg Arg Met Lys Trp Lys Lys 1 5 10 15 <210> 61 <211> 16 <212> PRT <213> Artificial sequence <400> 61 Arg Phe Ile Lys Ile Trp Phe Phe Phe Arg Arg Met Lys Trp Lys Lys 1 5 10 15 <210> 62 <211> 16 <212> PRT <213> Artificial sequence <400> 62 Arg Met Ile Lys Ile Trp Phe Gln Asn Arg Arg Met Lys Trp Lys Lys 1 5 10 15 <210> 63 <211> 16 <212> PRT <213> artificial sequence <400> 63 Arg Gln Ile Lys Ile Trp Phe Met Asn Arg Arg Met Lys Trp Lys Lys 1 5 10 15 <210> 64 <211> 16 <212> PRT <213> artificial sequence <400> 64 Arg Gln Ile Lys Ile Trp Phe Gln Met Arg Arg Met Lys Trp Lys Lys 1 5 10 15 <210> 65 <211> 16 <212> PRT <213> artificial sequence <400> 65 Arg Met Ile Lys Ile Trp Phe Met Asn Arg Arg Met Lys Trp Lys Lys 1 5 10 15 <210> 66 <211> 16 <212> PRT <213> artificial sequence <400> 66 Arg Met Ile Lys Ile Trp Phe Gln Met Arg Arg Met Lys Trp Lys Lys 1 5 10 15 <210> 67 <211> 16 <212> PRT <213> artificial sequence <400> 67 Arg Gln Ile Lys Ile Trp Phe Met Met Arg Arg Met Lys Trp Lys Lys 1 5 10 15 <210> 68 <211> 16 <212> PRT <213> Artificial sequence <400> 68 Arg Met Ile Lys Ile Trp Phe Met Met Arg Arg Met Lys Trp Lys Lys 1 5 10 15 <210> 69 <211> 16 <212> PRT <213> Artificial sequence <400> 69 Arg Phe Ile Lys Ile Trp Phe Gln Trp Arg Arg Met Lys Trp Lys Lys 1 5 10 15 <210> 70 <211> 16 <212> PRT <213> Artificial sequence <400> 70 Arg Trp Ile Lys Ile Trp Phe Gln Phe Arg Arg Met Lys Trp Lys Lys 1 5 10 15 <210> 71 <211> 16 <212> PRT <213> Artificial sequence <400> 71 Arg Trp Ile Lys Ile Trp Phe Gln Met Arg Arg Met Lys Trp Lys Lys 1 5 10 15 <210> 72 <211> 16 <212> PRT <213> Artificial sequence <400> 72 Arg Met Ile Lys Ile Trp Phe Gln Trp Arg Arg Met Lys Trp Lys Lys 1 5 10 15 <210> 73 <211> 16 <212> PRT <213> artificial sequence <400> 73 Arg Met Ile Lys Ile Trp Phe Trp Tyr Arg Arg Met Lys Trp Lys Lys 1 5 10 15 <210> 74 <211> 16 <212> PRT <213> artificial sequence <400> 74 Arg Trp Ile Lys Ile Trp Phe Tyr Pro Arg Arg Met Lys Trp Lys Lys 1 5 10 15 <210> 75 <211> 16 <212> PRT <213> artificial sequence <400> 75 Arg Tyr Ile Lys Ile Trp Phe Pro Ile Arg Arg Met Lys Trp Lys Lys 1 5 10 15 <210> 76 <211> 16 <212> PRT <213> artificial sequence <400> 76 Arg Pro Ile Lys Ile Trp Phe Ile Leu Arg Arg Met Lys Trp Lys Lys 1 5 10 15 <210> 77 <211> 16 <212> PRT <213> artificial sequence <400> 77 Arg Ile Ile Lys Ile Trp Phe Leu Val Arg Arg Met Lys Trp Lys Lys 1 5 10 15 <210> 78 <211> 16 <212> PRT <213> Artificial sequence <400> 78 Arg Leu Ile Lys Ile Trp Phe Val Ala Arg Arg Met Lys Trp Lys Lys 1 5 10 15 <210> 79 <211> 19 <212> RNA <213> Artificial sequence <400> 79 aacguuagcu ucaccaaca 19 <210> 80 <211> 19 <212> RNA <213> Artificial sequence <400> 80 uguuggugaa gcuaacguu 19 <210> 81 <211> 19 <212> RNA <213> Artificial sequence <400> 81 gcauguacca cgaguccaa 19 <210> 82 <211> 19 <212> RNA <213> Artificial sequence <400> 82 uuggacucgu gguacaugc 19 <210> 83 <211> 19 <212> RNA <213> Artificial sequence <400> 83 gcugcacucu ggcgacauu 19 <210> 84 <211> 19 <212> RNA <213> Artificial sequence <400> 84 aaugucgcca gagugcagc 19 <210> 85 <211> 6 <212> PRT <213> Artificial sequence <400> 85 Arg Arg Arg Arg Arg Arg 1 5 <210> 86 <211> 8 <212> PRT <213> Artificial sequence <400> 86 Arg Arg Arg Arg Arg Arg Arg Arg 1 5 <210> 87 <211> 10 <212> PRT <213> Artificial sequence <400> 87 Arg Arg Arg Arg Arg Arg Arg Arg Arg Arg 1 5 10 <210> 88 <211> 12 <212> PRT <213> Artificial sequence <400> 88 Arg Arg Arg Arg Arg Arg Arg Arg Arg Arg Arg Arg 1 5 10
Claims
1. A pharmaceutical preparation for co-delivering multiple therapeutic agents, which is a pharmaceutical preparation prepared using a drug delivery carrier, wherein the drug delivery carrier comprises a cationic liposome modified with a cell-penetrating peptide and a cationic material, wherein the cationic material is oligoarginine R8 shown in SEQ ID NO: 86; the cell-penetrating peptide is RWIKIWFQNRRMKWKK (SEQ ID NO: 24), RQIKIWFWNRRMKWKK (SEQ ID NO: 25), RQIKIWFQWRRMKWKK (SEQ ID NO: 26), RWIKIWFWNRRMKWKK (SEQ ID NO: 27), RWIKIWFQWRRMKWKK (SEQ ID NO: 28), RQIKIWFWWRRMKWKK (SEQ ID NO: 29), or RWIKIWFWWRRMKWKK (SEQ ID NO: 30); The cationic liposomes comprise the following membrane materials: (i) a cationic lipid, which is 1,2-dioleoyl-3-trimethylammonium-propane DOTAP; (ii) a non-cationic lipid, which is 1,2-di-(9Z-octadecanoyl)-sn-glycero-3-phosphoethanolamine DOPE; and (iii) cholesterol; The cell-penetrating peptide modification is carried out using membrane materials: (iv) polyethylene glycol-modified (PEGylated) phospholipids and polyethylene glycol-phospholipids conjugated with the cell-penetrating peptide, wherein: The PEGylated phospholipid is methoxy-polyethylene glycol-distearoyl phosphatidylethanolamine (mPEG-DSPE), and the polyethylene glycol phospholipid conjugated with the cell-penetrating peptide is cell-penetrating peptide-PEG-DSPE; and the polyethylene glycol chain lengths in the PEGylated phospholipid and the polyethylene glycol phospholipid conjugated with the cell-penetrating peptide are not equal, wherein the polyethylene glycol chain in the polyethylene glycol phospholipid conjugated with the cell-penetrating peptide is longer than the polyethylene glycol chain in the PEGylated phospholipid by 0.5 kDa-5 kDa; and the molar ratio of the membrane material (i): (ii): (iii): (iv) is 20-40: 20-40: 20-40: 1-20, and the polyethylene glycol phospholipid conjugated with the cell-penetrating peptide accounts for 40%-80% of the molar ratio of the membrane material (iv); The plurality of therapeutic agents comprises at least one non-nucleic acid therapeutic agent and at least one nucleic acid therapeutic agent, wherein the at least one non-nucleic acid therapeutic agent is a chemotherapeutic agent; the at least one nucleic acid therapeutic agent is selected from plasmid DNA, small interfering RNA (siRNA), miRNA, sense RNA, antisense oligonucleotide (ASO), aptamers, ribozymes; wherein a physical complex of a cationic material and at least one nucleic acid therapeutic agent is formed by mixing a cationic material and at least one nucleic acid therapeutic agent contained in a drug delivery carrier, wherein the charge ratio of the cationic material R8 and the nucleic acid therapeutic agent is 5:1; The method comprises preparing a liposome encapsulating at least one non-nucleic acid therapeutic agent by mixing a membrane material of a cationic liposome and at least one non-nucleic acid therapeutic agent, wherein the molar ratio of the non-nucleic acid therapeutic agent to the cationic lipid DOTAP in the cationic liposome is 1:1200, 1:1000, 1:500, 1:200, 1:100 or 1:5; Mixing the physical complex of the cationic material and at least one nucleic acid therapeutic agent with the liposome encapsulating at least one non-nucleic acid therapeutic agent to prepare a lipoplex, wherein the charge ratio of the cationic liposome to the nucleic acid therapeutic agent is 4:1; The lipid complex is modified with a cell-penetrating peptide to prepare the pharmaceutical preparation, wherein the lipid complex is mixed with a polyethylene glycol (PEGylated) phospholipid and a polyethylene glycol phospholipid conjugated with a cell-penetrating peptide to perform cell-penetrating peptide modification to prepare the pharmaceutical preparation; or wherein a physical complex of a cationic material and at least one nucleic acid therapeutic agent is formed by mixing a cationic material and at least one nucleic acid therapeutic agent contained in a drug delivery carrier, wherein the charge ratio of the cationic material R8 and the nucleic acid therapeutic agent is 5:1; The method comprises preparing a liposome encapsulating at least one non-nucleic acid therapeutic agent by mixing all membrane materials of a cationic liposome modified with a membrane-penetrating peptide and at least one non-nucleic acid therapeutic agent, wherein the molar ratio of the non-nucleic acid therapeutic agent to the cationic lipid DOTAP in the cationic liposome is 1:1200, 1:1000, 1:500, 1:200, 1:100 or 1:5; The pharmaceutical preparation is prepared by mixing the physical complex of the cationic material and at least one nucleic acid therapeutic agent with the liposome encapsulating at least one non-nucleic acid therapeutic agent, wherein the charge ratio of the cationic liposome to the nucleic acid therapeutic agent is 4:1; The molar concentration ratio of the non-nucleic acid therapeutic agent and the nucleic acid therapeutic agent in the pharmaceutical preparation is the IC 50 The ratio of values.
2. The pharmaceutical preparation according to claim 1, wherein the nucleic acid therapeutic agent is siRNA targeting brain tumors.
3. The pharmaceutical preparation according to claim 2, wherein the nucleic acid therapeutic agent is siRNA against c-myc of brain glioma.
4. The pharmaceutical formulation according to claim 1, wherein the chemotherapeutic agent is selected from carmustine (BCNU), docetaxel (DTX), gemcitabine, imatinib, cisplatin and doxorubicin (DOX).
5. The pharmaceutical preparation according to claim 1, wherein the polyethylene glycol chain in the polyethylene glycol phospholipid conjugated with the cell-penetrating peptide is longer than the polyethylene glycol chain in the PEGylated phospholipid by any value between 0.75 kDa and 4 kDa. 6 . The pharmaceutical preparation according to claim 5 , wherein the polyethylene glycol chain in the polyethylene glycol phospholipid conjugated to the cell-penetrating peptide is longer than the polyethylene glycol chain in the PEGylated phospholipid by any value between 1 kDa and 2 kDa.
7. The pharmaceutical preparation according to claim 1, wherein the cationic liposome comprises the following membrane materials: (i) DOTAP; (ii) DOPE; (iii) cholesterol; and the cell-penetrating peptide is modified with (iv) mPEG 2000 -DSPE and 89W Penetratin-PEG 3400 -DSPE modified, and the molar ratio of (i):(ii):(iii):(iv) is 20-40:20-40:20-40:1-20, and 89W Penetratin-PEG 3400 -DSPE accounts for 40% to 80% by mole in (iv).
8. The pharmaceutical preparation according to claim 7, wherein the molar ratio of (i):(ii):(iii):(iv) is 27.0-31.6:27.0-31.6:31.6-39.6:1-10, and 89W Penetratin-PEG 3400 -DSPE accounts for 40% to 80% by mole in (iv).
9. The pharmaceutical preparation according to claim 8, wherein the molar ratio of (i):(ii):(iii):(iv) is 28.5:28.5:38:5, 89W Penetratin-PEG 3400 - DSPE accounts for 40%, 45%, 50%, 55%, 60%, 65%, 70%, 75% or 80% by mole in (iv).
10. The pharmaceutical preparation according to claim 9, wherein 89W Penetratin-PEG 3400 - DSPE accounts for 60% by mole in (iv); The molar ratio of the non-nucleic acid therapeutic agent in the pharmaceutical preparation to the cationic lipid DOTAP in the cationic liposome is 1:1200, 1:1000, 1:500, 1:200, 1:100 or 1:5; The charge ratio of the cationic material R8 in the pharmaceutical preparation to the siRNA represented by SEQ ID NO:79 and SEQ ID NO:80 as the nucleic acid therapeutic agent is 5:1; The charge ratio of the cationic liposome to the siRNA shown in SEQ ID NO: 79 and SEQ ID NO: 80 as the nucleic acid therapeutic agent is 4:1, and The molar concentration ratio of the non-nucleic acid therapeutic agent and the nucleic acid therapeutic agent in the formulation is the IC 50 The ratio of values.
11. The pharmaceutical formulation of claim 10, wherein the non-nucleic acid therapeutic agent is DTX. 12 . The pharmaceutical preparation according to claim 1 , which is a pharmaceutical preparation for nasal administration.
13. Use of the pharmaceutical preparation according to any one of claims 1 to 12 for preparing a drug for treating brain tumors. The use according to claim 13 , wherein the brain tumor is a glioma.
15. Use of the pharmaceutical preparation according to any one of claims 1 to 12 for preparing a drug for treating lung tumors.
16. The use according to claim 15, wherein the lung tumor is lung adenocarcinoma.
17. Use of a drug delivery vector for preparing a drug formulation for delivery comprising at least one non-nucleic acid therapeutic agent and at least one nucleic acid therapeutic agent, wherein the drug delivery vector is as defined in claim 1, the at least one non-nucleic acid therapeutic agent is a chemotherapeutic agent; and the at least one nucleic acid therapeutic agent is selected from plasmid DNA, small interfering RNA (siRNA), miRNA, sense RNA, antisense oligonucleotides (ASO), aptamers, and ribozymes.
18. The use according to claim 17, wherein the chemotherapeutic agent is selected from carmustine (BCNU), docetaxel (DTX), gemcitabine, imatinib, cisplatin and doxorubicin (DOX).
19. A method for preparing the pharmaceutical preparation according to any one of claims 1 to 12, comprising (a) mixing a cationic material and at least one nucleic acid therapeutic agent contained in a drug delivery carrier to form a physical complex of a cationic material and at least one nucleic acid therapeutic agent, wherein the drug delivery carrier is as defined in claim 1, wherein the charge ratio of the cationic material R8 and the nucleic acid therapeutic agent is 5:1; (b) using a membrane material of a cationic liposome and at least one non-nucleic acid therapeutic agent to prepare a liposome encapsulating at least one non-nucleic acid therapeutic agent, wherein the molar ratio of the non-nucleic acid therapeutic agent to the cationic lipid DOTAP in the cationic liposome is 1:1200, 1:1000, 1:500, 1:200, 1:100 or 1:5; (c) mixing the physical complex of the cationic material and at least one nucleic acid therapeutic agent with the liposome encapsulating at least one non-nucleic acid therapeutic agent to prepare a lipoplex, wherein the charge ratio of the cationic liposome to the nucleic acid therapeutic agent is 4:1; (d) modifying the lipoplex with polyethylene glycolated (PEGylated) phospholipids and polyethylene glycol phospholipids conjugated with a cell-penetrating peptide; or include (a) mixing a cationic material and at least one nucleic acid therapeutic agent contained in a drug delivery carrier to form a physical complex of a cationic material and at least one nucleic acid therapeutic agent, wherein the drug delivery carrier is as defined in claim 1, wherein the charge ratio of the cationic material R8 and the nucleic acid therapeutic agent is 5:1; (b) using all membrane materials of the cationic liposome modified with a membrane-penetrating peptide and at least one non-nucleic acid therapeutic agent to prepare liposomes encapsulating at least one non-nucleic acid therapeutic agent, wherein the molar ratio of the non-nucleic acid therapeutic agent to the cationic lipid DOTAP in the cationic liposome is 1:1200, 1:1000, 1:500, 1:200, 1:100 or 1:5; (c) preparing the pharmaceutical preparation by mixing the physical complex of the cationic material and at least one nucleic acid therapeutic agent with the liposomes encapsulating at least one non-nucleic acid therapeutic agent, wherein the charge ratio of the cationic liposomes to the nucleic acid therapeutic agent is 4:1; The molar concentration ratio of the non-nucleic acid therapeutic agent and the nucleic acid therapeutic agent in the pharmaceutical preparation is the IC 50 The ratio of values.
